
==== Front
Signal Transduct Target Ther
Signal Transduct Target Ther
Signal Transduction and Targeted Therapy
2095-9907
2059-3635
Nature Publishing Group UK London

36906608
1375
10.1038/s41392-023-01375-x
Review Article
Synthetic biology-inspired cell engineering in diagnosis, treatment and drug development
Zhao Ninglin 1
Song Yingjie 2
Xie Xiangqian 3
Zhu Ziqi 1
Duan Chenxi 1
Nong Cheng 1
http://orcid.org/0000-0003-1585-6760
Wang Huan wanghuan@nju.edu.cn

3
http://orcid.org/0000-0002-6083-8716
Bao Rui baorui@scu.edu.cn

1
1 https://ror.org/011ashp19 grid.13291.38 0000 0001 0807 1581 Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
2 https://ror.org/043dxc061 grid.412600.1 0000 0000 9479 9538 College of Life Science, Sichuan Normal University, Chengdu, China
3 grid.41156.37 0000 0001 2314 964X State Key Laboratory of Coordination Chemistry, Chemistry and Biomedicine Innovation Center of Nanjing University, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, China
11 3 2023
11 3 2023
2023
8 1125 9 2022
31 1 2023
15 2 2023
© The Author(s) 2023
2023
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The fast-developing synthetic biology (SB) has provided many genetic tools to reprogram and engineer cells for improved performance, novel functions, and diverse applications. Such cell engineering resources can play a critical role in the research and development of novel therapeutics. However, there are certain limitations and challenges in applying genetically engineered cells in clinical practice. This literature review updates the recent advances in biomedical applications, including diagnosis, treatment, and drug development, of SB-inspired cell engineering. It describes technologies and relevant examples in a clinical and experimental setup that may significantly impact the biomedicine field. At last, this review concludes the results with future directions to optimize the performances of synthetic gene circuits to regulate the therapeutic activities of cell-based tools in specific diseases.

Subject terms

Cancer
Drug delivery
Biomarkers
Genetic engineering
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 81871615 81871615 81871615 81871615 81871615 81871615 81871615 81871615 Zhao Ninglin Song Yingjie Xie Xiangqian Zhu Ziqi Duan Chenxi Nong Cheng Wang Huan Bao Rui issue-copyright-statement© West China Hospital, Sichuan University 2023
==== Body
pmcIntroduction

Modern science is becoming highly multidisciplinary to promote the innovation of new theories and technologies. Synthetic biology (SB) is one of the fastest-growing and most dynamic multidisciplinary fields comprising different projects, approaches, and definitions.1–3 SB applies engineering principles to genetically design and transform cells or living organisms by constructing biological functional components, devices, and systems, creating or reinventing biological modules to meet human needs, or even creating novel biological systems.4 SB-inspired cell factory engineering for industrial applications, in a narrow concept, is about using renewable biomass resources as raw materials and synthetic assembly of existing components from microbial or animal cells to produce various products.5–7 Engineered and standardized functional modules are the strengths of SB. Appropriate interface design makes modules detachable, improving their stability and compatibility in different environments. Whole-genome synthesis, redesign, and reconstruction allow generating of artificial biomimetic/minimal cells, while atomic or module/domain-level protein engineering offers high specificity and controllability over more complex functions. Meanwhile, innovative modification and creative assembly of signaling and communication systems can further optimize cell engineering. In addition, mathematical models for functional module simulation and prediction help streamline circuit design for the development of invaluable research tools.8–10

Engineered cells can have various applications, including the production of industrial or pharmaceutical compounds and increasing agricultural productivity by alleviating pathogens and environmental challenges.11,12 SB-inspired cell engineering can be commercialized for medical and healthcare. The main goal of medical SB is to genetically modify cells and redesign/synthesize regulatory systems to assist in disease diagnosis and treatment.13,14 Such cell-based sensors and therapies could achieve more specific detection and treat diseases on a much broader scale.12,15,16 Medical SB utilizes rationally designed therapeutic gene circuits, which can be implanted into the human body via vectors to correct the targeted defect. SB-inspired cell engineering with efficient design, specificity, and control can maximize therapeutic effects while minimizing side effects.

There are several reviews on SB technologies for developing therapeutic strategies or improving clinical effectiveness; most of them covered different aspects or specific approaches of SB in medical applications (Fig. 1).17–26 The ongoing development of engineered cells-derived tools has attracted substantial public attention. Accordingly, this review summarizes the recent preclinical, clinical, and experimental data to discuss the benefits and limitations of SB techniques in cell engineering and biomedical research. Here, we elaborate on various SB-driven cell devices in diagnosis, treatment, and drug development. Also, we address the current and potential future challenges for SB and cell engineering in medical applications.Fig. 1 Synthetic biology-inspired cell engineering can be employed for various medical applications. Synthetic gene networks are uploaded into cells for disease diagnosis, cancer therapies, infectious diseases treatment, and drug discovery

Engineered cells for diagnosis

Accurate disease characterization and monitoring are critical for therapeutic planning and epidemiological records. However, most traditional diagnostic procedures involving pathological examination of biopsies cannot precisely detect the disease state in real-time and are time-consuming. Thus, there is an urgent need to enhance current medical diagnostics capabilities. SB-inspired cell engineering and programmable biosensors have focused on high-throughput biomolecular/pathogens identification and probing, which can improve clinical diagnosis and disease management protocols (Fig. 2 and Table 1).25,27,28 Here, we describe the emerging advances of SB-inspired cell engineering approaches in diagnostics that may speed up data acquisition with improved sensitivity, specificity, real-time quantification, and accuracy at a substantially lower cost.Fig. 2 Synthetic biology platforms for diagnostics. a Schematic representation of engineered bacteria sense-and-respond systems adopt disease biomarkers (orange quadrilateral) to sense disease, in turn, produce a diagnostic readout such as β-lactamase and green fluorescent protein (GFP) (green Pacman). b Applications of mammalian synthetic biology in diagnostics. Monitoring of allergic immune by engineered mammalian cell encoding the histamine sense-and-response device. The constitutively expressed histamine-responsive receptor HRH2 sense histamine and triggers an endogenous signaling cascade leading to expression of a reporter protein. c Phage-based diagnostics rely on engineered phage can specific recognition of target bacterial species. Once the engineered phage bound to the target cells, the genome is injected into it then the phage replicate and reporter gene expressed

Table 1 Advances in engineering cells for disease diagnosis

Disease	Biomarker	Reporter	Diagnostics feature	
Zinc deficiency	Zinc	Pigments	Zinc-responsive transcription factors Zur and ZntR are modules to respond extracellular concentrations of zinc37	
Diabetes	Glucose	Fluorescence	Glucose-responsive integrase expression cassette (PCpxP–integrase–pA) that expresses the green fluorescent protein (GFP) for glycosuria testing38	
Vibrio cholera infection	Cholera autoinducer 1 (CAI-1)	Colorimetric enzymatic reaction	CqsS-NisK quorum sensing block for cholera autoinducer 1 (CAI-1) detection44	
Staphylococcus aureus infection	Autoinducer peptide-I (AIP-I)	Yellow pigment p-nitrophenol	Agr quorum sensing (agrQS) from Staphylococcus aureus to detect autoinducer peptide-I (AIP-I)45	
Gut inflammation	Thiosulfate/tetrathionate	Colorimetric enzymatic reaction	Two-component signaling system ThsSR/TtrSR is engineered to detect thiosulfate/tetrathionate49,50	
Gut inflammation	Nitrate	Fluorescence	NarX-NarL two-component system in E. coli responds to nitrate51	
Liver tumors	Liver metastases	Bioluminescent	PROP-Z (programmable probiotics with lacZ) platform can report liver metastasis52	
Intestinal bleeding	Heme	Fluorescence	Probiotic biosensor based on the sensitivity to heme diagnosis of gastrointestinal bleeding in pigs53	
Allergic responses	Histamine	Citrine	Engineered HEK293 cells can sensing the extracellular histamine levels and triggering cAMP-induced SEAP (secreted alkaline phosphatase) expression65	
Hypercalcaemia	Calcium	Melanin	Engineered HEK293 cells monitor calcium levels and produce melanin visible through the skin66	
Yersinia pestis	Phage ΦA1122 with luxAB	Bioluminescence	Engineered a diagnostic phage for Yersinia pestis detection by bioluminescence reporter81	
Mycobacterium tuberculosis	Fluoromycobacteriophages	Bioluminescence	Microscopy-based method utilizing the reporter mycobacteriophage mCherrybombϕ for detection of M. tuberculosis82	
Listeria monocytogenes	Nanoluciferase (NLuc) -based phage	Bioluminescence	Engineered nanoluciferase (NLuc)-based phage reporters to identify Listeria monocyte83	

Prokaryotic cell-based diagnostics

In the past several decades, bacteria-based biosensors have been extensively used in the food, environment, and medical industries.29,30 Bacterial biosensors can rapidly adapt to test environments to sense biological substances both in vitro and in vivo. Bacterial sensors are preferred for selectivity, sensitivity, automation, miniaturization, and accuracy.31 Engineered bacterial sensors have been successfully used for the analysis of environmental pollutants.32,33 Many bacterial sensors with specific and sensitive gene circuits for the identification of biological signals can be used to detect widespread clinically relevant biomarkers in vitro, such as in serum and urine.34 In particular, certain symbiotic bacteria that colonize specific tissues and organs are believed to be feasible candidates for cell engineering to serve as in vivo tools for real-time diagnosis.28,35,36

Most bacterial-based diagnostic biosensors produce an easily measurable output in the form of a pigment or fluorescent protein upon identification of a target signal.37,38 For instance, Zur and ZntR zinc-responsive transcription factors (TFs) modules respond to extracellular concentrations of zinc and produce visible pigments; Escherichia coli cells integrated with this circuit can sense serum zinc levels to identify zinc deficiency.37 Such a bacterial sensor impacts multiple metabolite production pathways through a single TF, reduces diagnostic time, and explains results through visual inspection. Similarly, the glucose-responsive integrase expression cassette (PCpxP–integrase-pA), which expresses the green fluorescent protein (GFP), is an ideal reporter to test glycosuria; hydrogel beads immobilized bacteria containing this module can evaluate urine glucose levels in diabetic patients with high sensitivity and specificity.38

Quorum sensing (QS) systems that determine population behavior are widely distributed among bacteria and have a long evolutionary history.39 QS signaling molecule profiling from specific pathogens are proper biomarkers for bacterial diagnosis; acyl-homoserine lactone (AHL), 2-heptyl-4-quinolone (HHQ), and acyl-homoserine lactones (acyl HSLs) have been used to identify P. aeruginosa infection.40–42 Importantly, QS signals can be directly monitored by genetically engineered non-pathogenic bacteria.43 Mao et al. reprogrammed the probiotic Lactococcus lactis by introducing a chimeric CqsS-NisK quorum sensing block for the detection of cholera autoinducer 1 (CAI-1) from Vibrio cholerae.44 This system can easily detect V. cholerae in fecal samples and intestinal environments. Another research group generated a probiotic Lactobacillus reuteri strain integrated with an agr quorum sensing (agrQS) biosensor from Staphylococcus aureus, which could identify quorum sensing molecule autoinducer peptide-I (AIP-I) from common pathogenic Staphylococcus sp with high sensitivity in the nanomolar range.45 Engineered probiotic bacteria integrated with a rational antimicrobial module can be novel therapeutic “robots” to track and eliminate pathogenic bacteria.

Two-component system (TCS), including a membrane-bound histidine kinase for signal sensing/transduction and a cognate intracellular response regulator to activate downstream gene expression, is a key mechanism of how bacteria perceive and respond to the environment.46 The well-defined TCSs have been used for diagnostic signal analysis.47 Holowko et al. integrated three V. cholerae-derived TCS elements CqsS, LuxU, and LuxO with a dCAS9-based GFP-reporter system into E. coli to construct a biosensor with a high sensitivity for QS-ligand cholera CAI-1 indicating the presence and proliferation of V. cholera.48 Previous studies engineered thiosulfate/tetrathionate-responsive E.coli strain by combining TCS sensors ThsSR/TtrSR with pre-installed reporter system or phage lambda cI/Cro-based memory system as potential therapeutics and diagnostics for inflammation49,50 Recently, a new TCS-based whole-cell biosensor was designed by adopting E. coli NarX-NarL to sense nitrate levels, a biomarker of gut inflammation.51 This highly specific nitrate-responsive genetic circuit allows non-invasive diagnosis of inflammation-related diseases.

In addition to in vitro diagnosis, engineered bacteria systems can also be exploited for the diagnosis of complex internal environments. Biomolecular monitoring of the gastrointestinal environment is often limited by access and complexity of the environment. Danino et al. developed a PROP-Z (programmable probiotics with lacZ) platform using a Nissle 1917 (EcN) derived bacterium with a series of expression cassettes. This orally administered probiotic can produce detectable signals in urine reliably indicating hepatic tumors.52 Another exquisitely engineered micro-bio-electronic device (IMBED) was developed by Mimee et al. They efficiently combined a bacterial-electronic system with SB circuits, electronic sensor, and wireless transmission platform to detect excess heme in blood samples offering rapid in situ diagnosis of gastrointestinal bleeding in pigs.53

Eukaryotic cell-based diagnostics

Microbial biosensors offer inexpensive and feasible disease detection strategies. Similar to engineered bacteria, eukaryotic cell-based biosensors have also been developed for real-time clinical applications.

The number of yeast/fungi-based diagnostic biosensors is growing. Instead of using optical signals such as fluorescence, luminescence, and colorimetry, many yeast-based biosensors utilize electrochemical elements (amperometry, potentiometry, conductometry, voltammetry) and growth indicating modules (HIS3, TRP1, LEU2).54–56 One of the advantages of eukaryotic cell biosensors is to incorporate G-protein-coupled receptors (GPCRs) which greatly expands their functional repertoire.57–59 Diagnostic yeast biosensors have often been used to detect the metabolic rate of oxygen, glucose, lactate, and ethanol through enzyme-catalyzed oxidation-reduction reactions; the generated electrical energy is measured by an implemented electrode which rapidly generates signals with high sensitivity and specificity. A d-lactate-selective biosensor was developed from the debris of the recombinant thermotolerant methylotrophic yeast H. polymorpha. This biosensor overproduces d-lactate: cytochrome c-oxidoreductase (DLDH) and has high selectivity and effective stability for d-lactate due to the deletion of cytochrome c-oxidoreductase (CYB2, responsible for l-lactate synthesis) in the C-105 strain genotype (gcr1 catX).60 The same research group further suggested that enriching the flavocytochrome b2 (FC b2) module incorporated H. polymorpha cells by enzyme-bound nanoparticles can improve amperometric current responses.61

Combining new ideas and technologies based on existing yeast-based biosensors stimulates more innovations. Holly V. Goodson’s research group designed an S. cerevisiae-based olfactory reporter by assembling the endogenous galactose-response system and the gene encoding acetyltransferase I (ATF1, isoamyl alcohol-converting enzyme). This system produces enough amount of isoamyl acetate (banana flavor) in response to galactose and is suitable for low-cost non-quantitative/semi-quantitative diagnosis.62 Furthermore, biological paper analytical devices (bioPADs) were created by embedding this bioengineered fluorescent yeast biosensor into a portable paper substrate. This simple but sensitive test strip can detect doxycycline in complex matrices such as in human urine and raw bovine serum.63 It is foreseeable that sustainable developments in fungal genome engineering would take yeast biosensors toward precise, accurate, and cost-effective editing.

Based on the availability and compatibility of endogenous signal-transduction biomarkers, engineered mammalian cells are more suitable for certain diagnostics applications over bacterial and yeast biosensors.64 With the recent technological advances, a few mammalian cell-based diagnostics have been developed. For example, HEK293 cell-based biosensor with a synthetic histamine-responsive signal module (histamine receptor H2, HRH2) can detect allergies from blood samples of high-risk allergic patients by sensing the extracellular histamine levels and triggering the expression of cAMP-induced SEAP (secreted alkaline phosphatase).65 Such engineered mammalian cell systems can be used in high-throughput diagnostic applications such as testing novel drugs for allergic reactions. Many diseases are preceded by a period of asymptomatic pathogenesis and thus require reliable indirect molecular diagnosis methods. Accordingly, Martin Fussenegger’s research group designed a novel HEK293 cell for in vivo diagnostics by employing a calcium-sensing receptor constructed with a synthetic signaling pathway. In response to the increased calcium level in hypercalcemia, this system generates black pigment melanin on the skin via transgenic tyrosinase-mediated enzymatic reaction and thus is ideal for naked-eye detection.66

Except for epithelial cell lines, other mammalian cells including macrophages, neurons cell, mast cells, and B lymphocytes can also be exploited for biosensor applications. Based on the pattern of signal detection and test objective, a specific assay combined with proper cell lines can be used to assess pathogens, toxins, metabolic activity, or even cell proliferation.67 Monkey kidney cells (Vero cells) are sensitive to verotoxin Stx (Shiga-like toxins) due to their overproduced Stx receptor GB3 (globotriaosylceramide).68 Bioengineered Vero cells constructed in collagen matrix demonstrated better cell maturation and improved sensitivity to Stx and thus could detect Shiga-like toxin-producing pathogenic bacteria such as Salmonella, Listeria, Citrobacter, Serratia, and Hafnia.69 IgE-mediated vasoactive amines including histamine and serotonin degranulation are characteristics of basophil or mast cells, which make them a good choice for cell-based biosensor development.70 Jiang et al. reported an electrochemical sensor based on rat basophilic leukemia (RBL-2H3) cells exploited on folding paper-based equipment for casein detection.71 Certainly, engineered mammalian cell-based devices for therapeutic and diagnostic applications are a growing area of interest. The diverse cell behaviors in response to different compounds such as antibiotics, antibodies, and chemokines make mammalian cells attractive model for building diagnostic biosensors. Meanwhile, the complexity and packaging of eukaryotic genome have also to be considered when using them for such applications.

Phage-based diagnostics

Although cell-based biosensor diagnostics can fulfill most needs of clinical applications, the rational design of engineered phages promises some other advantages. Phages are viruses that infect bacteria by adhering to specific host cell surface receptors. A simple model for reporter phage design is that the presence of the correct epitope induces the transfer of the phage genome into bacteria, triggering bioluminescence from luciferase in the target bacteria.72,73 Bioluminescent reporter-based phages have been applied for the diagnosis of pathogens such as Bacillus anthracis,74,75 Vibrio parahaemolyticus,76 Salmonella typhimurium,77 pathogenic Escherichia coli,78,79 and Staphylococcus aureus.80 For example, an engineered Yersinia pestis phage was used for the detection of an etiologic agent in bubonic plague.81 A microscopy-based method in association with the fluoromycobacteriophage mCherrybombϕ was used to diagnose M. tuberculosis.82 Recently, Meile et al. engineered a set of nanoluciferase (NLuc)-based phage reporters to identify and differentiate Listeria monocytogenes in potentially contaminated milk, cold food, and other eatable samples.83 These NLuc-based reporter phages enabled rapid and ultrasensitive detection of one CFU of L. monocytogenes in 25 g of artificially contaminated natural food in less than 24 h.

Phages can also be exploited as bioelectrode elements by immobilizing them to an electrode surface or utilizing lytic phages to infect target bacteria to release bacterial cell contents such as adenosine triphosphate (ATP) for electrochemical detection.84 Niyomdecha et al. used an M13 bacteriophage-modified electrode for the detection of Salmonella spp.: this biosensor binds to target bacteria through the amino acid groups on the filamentous phage.85 Farooq et al. mobilized S. aureus-specific lytic phages in surface-modified bacterial cellulose (BC) matrix conducted by carboxylated multi-walled carbon nanotube (c-MWCNTs). The functionalized electrode could detect S. aureus through impedance measurements.86 Lately, gold electrodes were used as a transducer with chemically modified M13 phages to monitor caspase-3 activity in apoptotic HeLa cells with nanomole range sensitivity.87 Such bacterial cell and phage-based biosensors can effectively sense disease-associated biomarkers, paving the way for next-generation of medical diagnostics.

Engineered cell-based therapeutics for cancer

More than 19 million new cases of cancer are diagnosed every year, making it one of the most devastating diseases worldwide.88–90 Traditional cancer treatments such as surgical intervention, radiation, and chemotherapeutic drugs have several limitations, including high cytotoxicity and low selectivity.91–94 SB approaches for cancer treatment are the most vivid and promising trends that enable precise timing, location, and dosing of the drug. Accordingly, engineered mammalian and bacterial cells have been increasingly recognized as promising anticancer devices.95–97

Bacteria-derived tools for cancer treatment

Since some bacteria can colonize in a hypoxia intratumoral environment, human cancer can now be treated by SB-engineered bacteria.98–101 Certain bacterial species, including Streptococcus, Caulobacter, Escherichia, Bifidobacterium, and Salmonella, can automatically sense and accumulate in tumor tissues after external administration (injection or oral) to produce cytotoxic toxins or release delivery compounds.102 One of the major advantages of bacterial therapies for cancer is that they can be easily manipulated for the effective delivery of anticancer agents.103 Based on the reported studies, bacterial therapies for cancer majorly involves three types of mechanisms: expression of toxic proteins to directly kill cancer cells, immunotherapeutics that stimulate the immune system to kill cancer cells or the transfer of therapeutic drug delivery vehicles (Fig. 3 and Table 2).102,104,105Fig. 3 Engineered bacteria for cancer therapy. Current strategies can be divided into three types: a expression of toxic proteins to directly kill cancer cells, b immunotherapeutics, and c therapeutic drug delivery vehicles. a Bacteria could utilize secretion systems such as T3SS and T6SS to directly inject bacterial effector proteins into eukaryotic host cells, or secret effectors targeting receptors on cell surface. LRP laminin receptor precursor protein, EF-2 elongation factor 2. b Engineered bacteria could express cytokines or other chemical molecules to induce proper immune cells. IL-12 Interleukin 12, CTLA-4 cytotoxic T-lymphocyte-associated antigen-4, PD-1 programmed death-1, PD-L1 programmed cell death protein-ligand 1, nb nanobody. c Bacteria-based vaccine or drug delivery systems. VEGFR2 vascular endothelial growth factor 2, OVA ovalbumin

Table 2 Bacteria-based therapies against cancer in clinical trials

Type	Biological/tradename	Sponsor	NCT	Year	Phase	Status	Cancer type	
Salmonella Typhimurium	VNP20009	National Cancer Institute	NCT00004988	2008	I	Completed	Cancer neoplasm, neoplasm, metastasis297	
VNP20009	National Cancer Institute	NCT00006254	2013	I	Completed	Unspecified adult solid tumor298	
Salmonella-IL-2	Masonic Cancer Center, University of Minnesota	NCT01099631	2020	I	Completed	Solid tumor cancer299	
VXM01/Avelumab	Vaximm GmbH	NCT03750071	2021	I/II	Recruiting	Recurrent glioblastoma	
SGN1	Guangzhou Sinogen Pharmaceutical Co., Ltd.	NCT05103345	2021	I	Not yet recruiting	Advanced solid tumor	
Salmonella-IL-2	Salspera LLC	NCT04589234	2022	II	Recruiting	Metastatic pancreatic cancer	
VNP20009-M	Guangzhou Sinogen Pharmaceutical Co., Ltd.	NCT05038150	2022	I	Not yet recruiting	Advanced solid tumor	
Escherichia coli	SYNB1891/Atezolizumab	Synlogic	NCT04167137	2021	I	Recruiting	Metastatic solid neoplasm, lymphoma300	
VAX014	Vaxiion Therapeutics	NCT03854721	2020	I	Recruiting	Urothelial carcinoma of the urinary bladder301	
Clostridium novyi-NT	Clostridium novyi-NT spores	BioMed Valley Discoveries, Inc.	NCT01118819	2016	I	Terminated	Solid tumor malignancies	
Clostridium novyi-NT spores	BioMed Valley Discoveries, Inc.	NCT01924689	2019	I	Completed	Solid tumor malignancies302	
Bifidobacterium longum	bacTRL-IL-12	Iqvia Pty Ltd.	NCT04025307	2021	I	Terminated	Solid tumors	
APS001F/Flucytosine (5-FC)/10% maltose	Anaeropharma Science, Inc.	NCT01562626	2021	I/II	Suspended	Tumors, neoplasms, cancer	
Bifidobacterium animalis

lactis

	EDP1503/Pembrolizumab	Evelo Biosciences, Inc.	NCT03775850	2021	I/II	Completed	Colorectal cancer metastatic, triple-negative breast cancer, non-small cell lung cancer303

Bladder cancer, gastroesophageal cancer, renal cell carcinoma, MSI-H

	
Listeria monocytogenes	ADU-623	Providence Health & Services	NCT01967758	2018	I	Completed	Astrocytic tumors304	
CRS-207 with Epacadostat	Aduro Biotech, Inc.	NCT02575807	2019	I/II	Terminated	Platinum-resistant ovarian, fallopian, or peritoneal cancer	
ADXS31-142+ Pembrolizumab	Advaxis, Inc.	NCT02325557	2020	I/II	Unknown	Prostate cancer	
CRS-207 in combination with chemotherapy	Aduro Biotech, Inc.	NCT01675765	2020	I	Completed	Malignant pleural mesothelioma305	
ADXS11-001	Andrew Sikora	NCT02002182	2021	II	Active, not recruiting	HPV-positive oropharyngeal cancer306	
CRS-207	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	NCT03190265	2022	II	Active, not recruiting	Pancreatic cancer307	
ADXS-503 with or without pembro	Advaxis, Inc.	NCT03847519	2022	I/II	Recruiting	Metastatic non-small cell lung cancer	
Multi-species/strain

bacteria

	Dietary supplement: probiotic	Mayo Clinic	NCT03358511	2020	Not applicable	Completed	Breast cancer308	
MRx0518	4D pharma plc	NCT03637803	2021	I/II	Recruiting	Oncology, solid tumor, non-small cell lung cancer, renal cell carcinoma, melanoma, bladder cancer	
VE800 with Nivolumab	Vedanta Biosciences, Inc.	NCT04208958	2021	I/II	Active, not recruiting	Metastatic cancer	

Natural bacterial toxins are emerging as potential anticancer agents to treat established solid tumors.104 Bacterial extract from Streptococcus pyogenes and Serratia marcescens was shown effective against sarcomas, melanomas, and myelomas, and named “Coley’s toxins” based on the name of the researcher.106,107 Since then, more bacterial toxins have been identified and tested for anticancer therapy.102,104 Cytolethal distending toxins from Salmonella typhi and the cycle-inhibiting factor (Cif) from enterohemorrhagic E. coli can inhibit cancer cell growth by blocking mitosis.108,109 The bifunctional Pseudomonas aeruginosa exotoxin T (ExoT) consists of a GTPase-activating protein (GAP) and an ADP-ribosyltransferase encoded from the N- and C-terminus, respectively.110,111 The GAP protein guides the mitochondrial dysfunction in the host cell through activating host caspases 3 and 9, while the ADP-ribosyltransferase domain upon activating the CT10 regulator of the kinase (Crk) leads to atypical anoikis apoptosis.112,113 Clostridium perfringens enterotoxin (CPE) can treat colorectal cancers by binding to claudin-3 on the tumor cell surface forming a multi-protein membrane pore complex, altering cellular osmotic equilibrium that leads to cell lysis.114,115 To improve the specific recognition of bacterial toxins for cancer cells, they can be reprogrammed either to conjugate with tumor surface antigens or ligands that selectively bind to the target cell receptor.104,116 For instance, P. aeruginosa exotoxin A (PE) was fused to anti-CD25 to form a novel recombinant toxin.117 Native diphtheria toxin (DT) was linked with the B-subunit of Shiga-like toxin (STXB) to improve its affinity for breast cancer cells and showed improved cytotoxicity against Gb3-expressing cancer cells in a dose-dependent manner.118 Besides, bacterial spores can also be exploited as anticancer agents as they can specifically germinate inside the necrotic/hypoxic tissues such as a solid tumor.119,120 Clostridium histolyticum spores showed considerable oncolysis and tumor regression effects in murine models.121 However, the original bacterial spores might not eliminate cancer cells and would require genetic modifications or combinational use with other anticancer strategies such as radiotherapy and chemotherapy.

Expression of exogenous cytotoxic proteins may trigger the host immune response raising safety concerns while engineered bacteria to induce specific cytokines can be an alternative anticancer strategy.102 Selective expression of cytokines can induce proper immune cells to clear tumors via multiple mechanisms with fewer side effects.122 Interleukin-2 (IL-2) and IL-18 are the most crucial components of cancer-related inflammation and participate in the immune regulation network. They activate the antitumor cytotoxicity of T cells and natural killer cells.123,124 Engineered Salmonella producing IL-2 and IL-18 was shown to inhibit tumor growth in animal experiments.125,126 Targeting programmed cell death protein-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) by immune-checkpoint inhibitors is a revolutionary cancer immunotherapy strategy but has side effects such as fatigue, skin rashes, and endocrine disorders.127,128 Increasing l-arginine levels in tumor tissue can activate the response of immune-checkpoint inhibitors. Engineered E. coli Nissle 1917 strain after accumulation in the tumor tissue converted ammonia to l-arginine recruiting tumor-infiltrating T cells showing a remarkable antitumor effect.129 Gurbatri et al. engineered a probiotic bacteria system to tightly control the release of nanobodies, which targeted PD-L1 and CTLA-4 and activated T cells.130 In another case, engineered Salmonella (△ppGpp) was utilized to secret the development endothelial locus 1 (Del-1) protein promoting the recruitment of M1 macrophage to tumors.131

The deoxygenated inflammatory microenvironment of a tumor is distinct from most other tissues and therefore allows selective accumulation of obligate anaerobes in the tumor for the delivery of bacteria-based vaccine or drug.102,105 Hu et al. used self-assembled synthetic nanoparticles coated attenuated bacteria to develop a novel oral DNA vaccine to express vascular VEGFR2 and specific antigens.132 This engineered bacteria could activate T cells and induce the production of cytokine for efficacious cancer immunotherapy. In 2017, researchers exploited demi-bacteria (DB) from Bacillus for the efficient accommodation of antigen and cytidine-phosphate-guanosine (CpG) adjuvants, inducing synergistic cellular and humoral immune responses in vivo.133 In combination with traditional chemotherapy and/or phototherapy, SB approaches can significantly promote the anticancer therapeutic outcome. For instance, attenuated Salmonella coated with degradable polydopamine was used for the delivery of photothermal agents to tumors.134 To efficaciously transport the chemotherapeutic drugs to the intestinal environment, Bacillus coagulans spores were modified with deoxycholic acid (DA) and then load them with drugs serving as autonomous nanoparticle (NP) producers.135 In addition, the bacteria-derived outer membrane vesicles (OMVs) have been explored as drug carriers in vaccine developments and cancer therapies.136,137 Based on oxygenated PDT and immunotherapy, Zhang et al. combined Chlorin e6 (Ce6) with negatively charged catalase (CAT) to form a molecular scaffold (CAT-Ce6) and transported it using aPDL1 modified (OMV-aPDL1) Salmonella OMVs to inhibit tumor growth.138

CAR-T-based cellular immunotherapy

Engineered cellular immunotherapy has great potential for advanced hematological malignancies and other solid tumors.139 Compared with traditional treatment and engineered bacterial and cell-based therapies have two major advantages: (1) a large number of basic research, clinical trials, and SB can make rapid development in this field, and (2) it offers long-term precise regulation and coordination of immune response in vivo. Current cancer cell therapy includes chimeric antigen receptor (CAR)-T cell, T-cell receptor (TCR) T cell, CAR-natural killer (NK)/NKT cells, tumor-infiltrating lymphocyte (TIL), choline transporter‐like proteins, etc.140 Among them, CAT-T-cell therapy is one of the most innovative gene therapies with the greatest breakthrough in the field.141,142 At present, five cell therapies have been approved by the Food and Drug Administration (FDA) in July 2021 after clinical trials and all of them are CAR-T-cell therapies (Table 3).140 Claudin18.2-specific CAR-T cells (CT041) showed good efficacy against digestive tract solid tumors with 48.6% objective remission rate and 73.0% disease control rate exceeding the best result of CAR-T-cell therapy for hematoma treatment (remission rate <30%).143 In the last decade, CAR has been developed to the fourth generation, the present CAR consists of a single-chain variable fragment (scFv), a flexible hinge, a transmembrane domain (CD8a), one or more co-stimulatory domains, and an intracellular CD3ζ domain from the T-cell receptor.139 Here, we discuss the main SB strategies for antitumor CAR engineering, including switchable control, logic gates, and armored CARs, and then discuss the future possible development of cell therapies from a SB perspective (Fig. 4).Table 3 Currently CAR-T products approved by FDA for cancer therapy

Product name	Target	Sponsor	First time offered to market	Approved countries	Vector	Cancer type	
Kymriah (tisagenlecleucel)	CD19	Novartis	September 30, 2017	USA (2017), EU (2018), Canada (2019), Japan (2019)	Lentivirus	B-cell acute lymphoblastic leukemia309	
Yescarta (axicabtagene ciloleucel)	CD19	Kite Pharma, Inc./Gilead Sciences lnc.	October 18, 2017	USA (2017), EU (2018), Canada (2019)	Retrovirus	Relapsed/refractory diffuse large B-cell lymphoma, relapsed/refractory primary mediastinal B-cell lymphoma, relapsed/refractory transformed follicular lymphoma, relapsed/refractory high-grade B-cell lymphoma310	
Tecartus (Brexucabtagene autoleucel)	CD19	Kite Pharma, Inc./Gilead Sciences lnc.	October 28, 2020	USA (2020), EU (2020)	Retrovirus	Relapsed/refractory mantle cell lymphoma311	
Breyanzi (lisocabtagene ciloleucel)	CD19	Juno Therapeutics, Inc/BMS	February 5, 2021	USA (2021)	Lentivirus	Relapsed/refractory diffuse large B-cell lymphoma, relapsed/refractory primary mediastinal B-cell lymphoma, relapsed/refractory transformed follicular lymphoma, relapsed/refractory high-grade B-cell lymphoma312	
Abecma (idecabtagene vicleucel)	BCMA	Celgene Corporation/BMS	March 26, 2021	USA (2021)	Lentivirus	Multiple myeloma313	
Carvykti (Ciltacabtagene autoleucel)	BCMA	Legendbiotech, Johnson & Johnson	February 28, 2022	USA (2022)	Lentivirus	Recurrent or refractory multiple myeloma314	

Fig. 4 Synthetic Biology in CAR-T Cell Engineering for cancer therapy. Current strategies can be divided into three types: a Switchable CAR, b Logic gates, and c Armored CAR. a Switchable CAR includes ON switches and OFF switches. In ON switches, exogenous molecules could activate the expression of CAR elements or the recombination for activate state. In OFF switches, the exogenous molecules induce the suicide genes such as iCasp9 for controlled elimination. Tet tetracycline, TRE tetracycline response element, FKBP a rapamycin-binding protein, AP21967 rapamycin analog, AP1903 dimer inducers. b Logic gates includes AND Gate, NOT Gate, and OR Gate. The activation of CAR depends on the number and type of antigens from tumor cells. Ag antigen. c As for Armored CAR-T, CAR-T cells are engineered to expression extracellular proteins including IL-12, IL-18, other enzymes or transmembrane ligands or receptors to enhance immune response. Intracellularly engineered CAR-T cell is another powerful strategy, such as inhibiting the transcription of immune-checkpoint molecules by shRNA or CRISPR-Cas9. IL-12 Interleukin 12, CpNA C. perfringens neuraminidase, CD40 cluster of differentiation 40, CD40L CD40 ligand, shRNA short-hairpin RNAs, CTLA-4 cytotoxic T-lymphocyte-associated antigen-4, PD-1 programmed death-1

Engineered switches are powerful control systems that minimize the life-threatening toxicities and other unfavorable side effects of CAR-T cells and have two types, named ON and OFF switches.26,144 A good example is the tetracycline regulatory platform, in which, exogenous tetracycline or doxycycline triggers the time- and dose-dependent expression of CAR components. The co-stimulatory domain could also be separated from the CAR structure and fused with small molecules binding domain for specific recognition and recombination. In addition, the antigen binding region can be engineered to recognize multiple tumor antigens, such as leucine zippers, unique epitopes, or chemical tags.145 In contrast to an ON switch, an OFF switch senses inhibitory signals to stop CAR T-cell activation. The drug-inducible caspase-9 (iCasp9) kill switch is one of the most successful designs, which has been used in several clinical trials for CAR T-cell therapies.146 The iCasp9 switch consists of a domain encoding chemically inducible dimerization system derived from FKBP12 (a rapamycin-binding protein) and split caspase-9 protein; the small-molecule AP1903 can induce the dimerization of FKBP12-caspase-9 causing apoptosis. CAR-T cells carrying the iCasp9 switch have shown effective curative effects in several clinical trials.147,148 There are other non-caspase strategies, such as combining MyD88 and CD40, based on the FKBP12/AP1903 dimerization system, that can overcome the limitation of elimination from the body.149

Considering the sophisticated tumor microenvironment and nonspecific antigens on tumor cells, more precise treatments are necessary to balance safety and efficacy. Improved genetic logic circuits, including AND Gate, NOT Gate, and OR Gate, were designed to solve these problems.144 All of the antigens present in AND Gate are needed for CAR-T-cell activation. Another common strategy is to separate and fuse the activation signal (CD3ζ) and the co-stimulatory domain to two different antigen-recognizing receptors, such as SynNotch system,150 bispecific tandem CAR (TanCAR)151 and masked CAR (mCAR),152 however, this also has the disadvantage of slow activation kinetics. Following the principle “A and not B”, NOT Gate can restrict off-target attacks of T cells reducing unintended immune attacks; however, this has not been validated in clinical trials so far. Alternatively, the purpose of OR Gate is to overcome antigen heterogeneity and antigen escape, thus multiple-targeting CAR-T therapy is developed by fusing different CAR-T cells or generating specific T cells with different CAR suits. The other two alternative strategies are combining different antigen targeting adapters and generation of bispecific CAR-T cells consisting of two or more different scFvs; however, the concerns of potential cytokine release syndrome, neurotoxicity, and B-cell aplasia remain.144

Another strategy for enhancing the antitumor efficacy of the CAR-T cells is to delete or express immunologic factors rather than CAR, named “Armored” CAR-T cells.153,154 Engineered CAR-T cells can secrete extracellular cytokines (including IL-12,155 IL-15,156 and IL-18157), antibodies, and bacterial enzymes increasing the prodrug concentration at the disease site.158 C. perfringens neuraminidase (CpNA) can remove sialic acid residues from the target cells. CpNA-restrained CAR-T cells exhibited superior effector function and cytotoxicity in vitro, showing enhanced antitumor efficacy in a Nalm-6 xenograft model of leukemia, xenograft model of glioblastoma, and syngeneic model of melanoma.159 Enabled CAR-T cells with additional natural or genetically modified transmembrane proteins can have more physiological functions such as signal transduction, recognition, and attachment. Kuhn et al. developed CAR-T cells to produce CD40L, a TNF-associated activation protein (TRAP), to recruit and activate immune effectors.160 Moreover, engineered CAR-T cells disturbing the intracellular transduction of inhibitory signaling pathways is another powerful strategy to inhibit the expression of immune-checkpoint molecules, including short-hairpin RNAs or CRISPR-Cas9.161,162

Although CAR-T therapy offers spectacular therapeutic opportunities against cancer, it has certain limitations such as tumor antigen escape relapse lowering the therapeutic efficacy. To conquer such challenges, novel strategies to optimize the CAR-T cells are needed for increased safety.

Certainly, the developments in SB will continue to promote the progress of tumor treatments; designing subtle gene circuits and finding novel biological components and the right targets could be the main endeavors. Meanwhile, controlling biosafety and reducing in vivo toxicity will also be necessary to balance cost and effectiveness.

Engineered cell-based therapeutics for infectious diseases

Infectious diseases are the major reasons for death and disability worldwide.163 Pathogenic infections including those from bacteria, fungi, and viruses are treated by conventional antibiotic therapy, however, many antibiotics have side effects causing intestinal flora disorder, hearing impairment, nephrotoxicity, and allergic reactions. Moreover, the emergence of multidrug-resistant (MDR) bacteria urgently demands new treatment strategies.164,165 The developing SB could also provide efficient, accurate, and cost-effective tools to treat infectious diseases. Here, we mainly discuss novel strategies against infectious diseases from the SB perspective.

SB tools against bacteria

Bacteria evolved with a variety of molecular weapons to kill or interfere with competitors, such as bacteriocins, effector proteins, and other chemicals.166–168 Thus, engineered bacteria can be exploited for novel antimicrobial biotherapeutics. Jana et al. introduced the arabinose-induced Type VI Secretion System (T6SS) into Vibrio natriegens, a safe bacterium, to manipulate the effector against competitors.169 Ting et al. developed programmed inhibitor cells (PICs), a new system expressing surface nanobodies to mediate antigen-specific cell-cell adhesion, exerting T6SS antimicrobial activity directly against selected bacteria.170 Bacteria use chemical language, termed quorum sensing (QS), to communicate in the community and regulate cell density.168 Probiotic E. coli designed to produce AI-2, which is naturally produced by Vibrio cholera, caused significant growth inhibition of V. cholerae and increased the survival rate of infected animals.171 Engineered Δalr ΔdadX E. coli Nissle 1917 strain can produce Dispersin B, Pyocin S5, Lysin E7, and sense autoinducer 3OC12HSL secreted by P. aeruginosa.172 In the presence of 3OC12HSL, this E. coli strain triggers E7 lysozyme-mediated self-lysis releasing Pyocin S5 and Dispersin B that kills P. aeruginosa. In another case, attenuated human lung pathogen Mycoplasma pneumonia was reformed to secrete anti-biofilm microbial enzymes that degraded Staphylococcus aureus biofilm both in in vitro and in vivo.173 Lysostaphin-producing Staphylococcus simulans could treat methicillin-susceptible and methicillin-resistant Staphylococcus aureus infections.174 Although bacteria can be easily tailored to combat microbial pathogens, their use is limited by the on/off switch of effector release, potential toxic effects in human cells, and long-term stability.175 A new research direction has evolved combining Computer-Based Frameworks and SB for the discover of potential antimicrobial peptide (AMP).176

Producing selective endolysins (lysins) to break bacterial cells, bacteriophages are one of the most effective therapeutic approaches against both Gram-positive and Gram-negative bacteria.177,178 Furthermore, engineered bacteriophage may overcome the limitations of frequent escape of bacterial hosts by modifying cell-wall related receptors, CRISPR-Cas disruption, or restriction-modification systems. E. coli bacteriophage T7 encoding depolymerase Dispersin B (T7DspB) could specifically hydrolyze polymeric b-1,6-N-acetyl-D-glucosamine (PNAG) of bacterial biofilms reducing biofilm formation of E. coli.179 Masuda et al. generated recombinant lnqQ-T7 phage by integrating lnqQ (structure gene of Leaderless bacteriocins, LLB, lacticin Q) into the T7 phage genome, which significantly inhibited lacticin Q-susceptible Bacillus coagulans and E. coli.180 Hsu et al. engineered λ phage to express transcriptional repressor of Shiga toxin (Stx), which successfully reduced Shiga toxin production in the E. coli population colonizing the intestinal tract model.181 The phages can also effectively transport molecules (such as proteins, peptides, DNA, RNA, and drugs) to targeted bacteria. Staphylococcus aureus phage encoding an antimicrobial small acid-soluble spore protein (SASP) was developed to kill S. aureus.182 This engineered phage (SASPject PT1.2) showed 100% activity against the 225 geographically diverse S. aureus isolates. However, bacteriophage treatment will inevitably lead to bacteriophage resistance and serious side effects such as the release of bacterial endotoxins. Also, bacteriophage is highly specific and attacks limited bacteria. In future, SB and genome engineering can expand the scope of phage therapy.182

SB tools against viral infection

SB-based tools can also contribute to the quick diagnosis, therapy, and prevention of viral infections.26 Wei et al. engineered Lactobacillus jensenii, a commensal bacterium that colonizes the cervicovaginal mucosa, to prevent HIV transmission; the engineered strain secretes two-domain CD4 (2D CD4) proteins,183 which associate with HIV type 1 (HIV-1) gp120 and inhibit HIV-1 invasion. Similarly, the probiotic bacterium E. coli Nissle 1917 was designed to secret HIV-gp41-hemolysin peptides, which blocks HIV fusion and subsequent invasion.184 This engineered strain could continuously and stably colonize the colon and cecum and released anti-HIV peptides for several months in mice. Furthermore, a genetically modified Lactobacillus acidophilus ATCC 4356 expressing human CD4 receptors on its surface can adsorb HIV-1 particles.185 The results showed that CD4-carrying bacteria could capture HIV-1 particles and attenuate infection efficiency in vitro. Martins et al. developed a potential microfluidic attenuator containing engineered E. coli to trap Ebola viruses in human blood.186 Along these lines, incorporating engineered probiotics into the vaginal microbiota can inhibit the spread of viruses.

Recently, COVID-19 (SARS-CoV-2) pandemic became a serious concern for public health safety,187,188 urgently requiring an efficient vaccine. Chen et al. engineered yeast to stably express the SARS-CoV-2 receptor binding domain (RBD) without impacting protein structure and functionality, which can be a promising candidate vaccine for COVID-19.189 Furthermore, the yeast expressed RBD combined with the 3M-052-alum provoked powerful immune response against SARS-CoV-2 in rhesus monkeys.190 Apart from recombinant proteins, nucleic acid-based (such as messenger RNA) vaccines are potential candidates against SARS-CoV-2. mRNA vaccines can transform host cells into “protein factories”, providing in situ the protein for a balanced immune response for both cellular and humoral immunity. In 2021, clinical trials demonstrated that 2 doses of mRNA vaccine BNT162b2 successfully induced a persistent germinal center B-cell response and robust humoral immunity. This made BNT162b2 to be the first licensed mRNA vaccine against COVID-19 by FDA for people over 16 years of age. Although a considerable number of mRNA vaccines have recently been developed, including PTX-COVID-19-B, SYS6006, and mRNA-LNP, they have several limitations including allergic reactions, uncertain immunity length, and difficult storage.191 Notably, SB tools also can help predict and identify the emerging SARS-CoV-2 variants. Based on reverse genetics, Thao et al. developed a rapid and robust yeast-based synthetic genomics platform for the genetic reconstruction of SARS-CoV-2, which can help generate and functionally characterize evolving viral variants in real-time.192 Scientists have used yeast screening to identify antibody escape mutants of SARS-CoV-2 S RBD to provide new therapeutic strategies against SARS-CoV-2. Importantly, viruses are evolutionarily autonomous; the emergence of new mutations led to the rapid global evolution of influenza viruses.193,194 Accordingly, the virus evolutionary genetic algorithm should be applied for the development of next-generation SB tools.

Engineered cell-based therapeutics for imbalanced flora-related diseases

The human body is inhabited by a multitude of microbial communities, which co-evolve with human hosts and are essential for their health.195–197 It is now well-established that human microbiome disturbance can lead to many chronic diseases, such as colorectal cancer (CRC), autism, and diabetes mellitus (DM).72,198–201 Microbial population modulation is a new treatment strategy for intestinal and neurodegenerative diseases (Fig. 5).105Fig. 5 Microbial modulation for disease treatment. AD Alzheimer’s disease, PD Parkinson’s disease, CRC colorectal cancer, DM diabetes mellitus, CDI Clostridium difficile infection, IBD inflammatory bowel disease, AS atherosclerosis

Intestinal diseases

Clostridium difficile infection (CDI), which causes gut dysbiosis, is a major cause of morbidity and death worldwide.202,203 Supplementation with Firmicutes, which convert primary bile acids to secondary bile acids, can significantly lower the growth and virulence of C. difficile by competitively colonizing the infected gut.204 Microbiome product Seres SER-262, which was isolated from healthy donors, could eradicate C. difficile infection. Altered composition, function, and metabolites of the intestinal flora have been associated with the progression of inflammatory bowel disease (IBD).205 Traditional IBD treatment is limited by side effects and complications. Lee et al. developed a hyaluronic acid-bilirubin nanodrug (HABN) which after accumulation restored the epithelial barrier alleviating inflamed colonic epithelia by restoring gut microbiota balance.206 Whelan et al. engineered the probiotic bacterium E.coli Nissle 1917 for the treatment of IBD, which secretes nematode immunomodulator cystine in the intestine.207 This modified probiotic significantly inhibited gut inflammation in murine acute colitis and can potentially treat other similar diseases. A Lactobacillus probiotic was engineered to produce anti-inflammatory molecules, in particular IL-10, in response to murine colitis.208 An engineered E. coli, named EcNL4, improved intestinal microbiota and thereby colitis in mice through the sustainable release of (R)-3-hydroxybutyric acid (3HB).209 An E. coli strain, named SYNB1618, expressing the phenylalanine ammonia-lyase and L-amino acid deaminase genes was engineered to consume phenylalanine in the gut. Overall, the above studies indicated that engineered bacteria can be potentially used to treat rare metabolic diseases.

Neurodegenerative and other diseases

Neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) have similar features.210 Emerging evidence closely associates gut dysbiosis with the development of neurodegenerative diseases through the gut–microbiota–brain axis.211,212 Wu et al. showed that Enterobacteria infection strongly exacerbated neurodegeneration by promoting the recruitment of immune hemocytes to the brain.213 Being functionally related to the brain immune system, the intestine has been termed the “second brain”. A study showed that oral administration of engineered MG136-pMG36e-GLP-1 strain derived from Lactococcus lactis MG1363 continuously produced Glucagon-like peptide-1 (GLP-1), which dramatically reduced lipopolysaccharide (LPS)-induced memory impairment and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced motor dysfunction, and the abundance of Enterococcus and Proteus pathogens in mice.214,215 This strain could be a novel intervention in AD and PD.214–221 Notably, probiotics can compete with pathogenic bacteria for nutrients and binding sites and secrete/produce bacterio-toxins which repress the invasion and adhesion of pathogens.218 Oral bacteriotherapy with SLAB51 probiotic and p62 (SQSTM1)-engineered lactic acid bacteria inhibited the progression of AD, indicating the positive effect of the probiotic intervention in neuronal diseases.219 So far, Lactobacillus and Bifidobacterium strains are the most promising candidates for improving cognitive functioning by reducing the levels of oxidative and inflammatory biomarkers in AD.220

Engineered commensal bacteria also have significant potential in other chronic diseases, i.e., DM and Atherosclerosis (AS). Duan et al. engineered Lactobacillus gasseri ATCC 33323 to secrete GLP-1 (1–37) to stimulate the conversion of intestinal epithelial cells into insulin-secreting cells in a diabetic rat model. They showed that rats fed daily with engineered bacteria developed insulin-producing cells in the upper intestine, sufficient enough to ameliorate hyperglycemia.214 A recent study showed that an engineered strain MG1363-pMG36e-GLP-1 (M-GLP-1) dramatically decreased body weight and improved glucose intolerance in high-fat diet (HFD) obese mice.215 May-Zhang et al. developed a novel E. coli Nissle 1917 strain expressing N-acyl phosphatidylethanolamines, which are precursors of endogenous lipid satiety factor N-acylethanolamides; the strain significantly reduced the levels of adiposity, hepatic triglycerides, and fatty acid synthesis lowering serum cholesterol levels and extent of necrosis in atherosclerotic mice.217

Similar to chemical drugs or cell-based therapies, the safety, tolerability, and efficacy of engineered therapeutic microbes for chronic disease therapies have attracted widespread attention.221 The long-term persistence, potential sensitization, and influence of engineered probiotics on native gut microbiota are yet to be completely comprehended. With the advances in SB tools and massive clinical trial data, this field is anticipated to develop therapies for many chronic diseases in the future.

Synthetic cells in drug discovery and development

Microorganisms, plants, marine resources, insects, and even mammals have always been important sources of pharmaceuticals/natural compounds. In nature, such compounds exist in low concentrations and are often difficult to synthesize due to their structural complexity. Advances in SB allow the production of bioactive compounds in non-natural hosts, which has revolutionized the pharmaceutical industry. Using computational and experimental tools, SB can help design chassis cells as novel drug screening platforms or as biofactories for the production of difficult bioactive compounds (Fig. 6).Fig. 6 Synthetic biology facilitates drug production in diverse chassis systems. Outlined scheme of the typical pipeline of drug development consisting of pathway elucidation, chassis selection and drug production. Gray arrow indicates extraction of bioactive compounds from natural sources, red arrows indicate general synthetic biology pathways. a Synthetic biology production of amorphadiene in E. coli chassis. b Synthetic biology production of taxadiene in S. cerevisiae chassis

SB in drug discovery

E. coli is the best-studied prokaryotic model organism with properties of a well-defined genetic background, rapid reproduction, low cost, and high levels of foreign protein expression. Therefore, it serves as an important component of high-throughput drug screening platforms. For example, multidrug-resistant E. coli strains are utilized to identify novel antimicrobial compounds.222 Male et al. developed a high-throughput gene coding screening platform to screen a SICLOPPS library of cyclic hexapeptides in E. coli that could inhibit the protein interaction between the human CMG2 receptor and the Bacillus anthracis protective antigen (PA).223 Van der Donk and co-workers generated a bicyclic peptide library in E. coli by combining the generation of a lanthipeptide library with a bacterial reverse two-hybrid peptide library (RTHS), and identified interaction inhibitors for the HIV p6 protein and UEV domain of the human TSG101 protein.224

E. coli lack the regulation mechanisms of eukaryotic gene expression and therefore is not suitable for screening bioactive compounds against eukaryotic targets.225 Saccharomyces cerevisiae is a commonly used eukaryotic model organism for the expression of active eukaryotic proteins undergoing post-translational modifications, including disulfide bond formation and glycosylation. In addition, S. cerevisiae can also tolerate a wide range of pH and high osmotic pressure, which makes it a robust organism in practice.226 S. cerevisiae strains, such as a yeast strain expressing human PARP1, have been used to screen inhibitors of enzymes involved in cancer progression.227 A yeast-based chemogenomic platform was used to identify the interaction between the chemotherapeutic agent methotrexate and the protein Dfr1 using haploinsufficiency profiling.228

The complexity of mammalian cells limits their engineering as host cells. However, recent developments in SB are changing the situation. For example, CRISPR-Cas9 technology was applied to create a high-throughput platform of primary human CD4+ T cells for the functional analysis of host factors in HIV infection and pathogenesis.229 Mammalian cells, such as Chinese hamster ovary (CHO) cell lines, are used for primary screening and production of complicated biopharmaceuticals. We will now discuss gene circuits based on mammalian cells. The mammalian cells have a high cost of production and also suffer from the risk of contamination from human-specific pathogens.

Synthetic gene circuits offer a huge opportunity for advanced drug discovery. Antimicrobial resistance (AMR) is emerging as a serious health threat, which can possibly be addressed by synthetic biology. Synthetic mammalian gene circuits can be used for the screening of novel antimicrobial compounds. Streptogramin-inducible (PipON) and streptogramin-repressible (PipOFF) mammalian gene-regulation systems were constructed based on the pristmamycin-responsive interaction between pristinamycin-induced protein (Pip) and its ptr promoter (Pptr) target sequence.230 The Streptomyces coelicolor Pip was adapted to modulate reporter gene expression (SEAP, secreted alkaline) in Chinese Hamster Ovary (CHO) cells in response to streptogramin antibiotics. This screening allowed the identification of new bioavailable and more sensitive antibiotics.231 Another example is the discovery of new anti-tuberculosis drugs. Ethylthionamide repressor (EthR)-based genetic circuit screening was used to identify 2-phenylethyl-butyrate, an anti-tuberculosis drug candidate against multidrug-resistant M. tuberculosis.232,233

SB in natural drug production

Natural products are a valuable source of pharmaceuticals; however, they are difficult to synthesize and exist in low amounts in natural hosts. Rapid advances in SB now allow the production of high-value natural medicines and precursor compounds (Table 4).Table 4 Advances in the research of high-value natural drugs and precursor compounds

Target drugs	Host	Products	Achievements	
Artemisinin	E. coli	Amorphadiene	First production of artemisinin precursors in a microbial system239	
S. cerevisiae	Artemisinic acid	The synthesis of artemisinic acid in S. cerevisiae was achieved240	
N. tabacum and P. patens	Artemisinin	Production of artemisinin in model plants242,243	
Paclitaxel	E. coli	Taxadiene	The first report of taxadiene production in E. coli250	
E. coli	Taxadiene	Taxadiene accumulation to 1 g/L.251	
S. cerevisiae	Taxadiene	Taxadiene accumulation to 129 ± 15 mg/L in S. cerevisiae252	
E. coli and S. cerevisiae	Oxygenated taxanes	Combining the strengths of E. coli and S. cerevisiae produced 33 mg/L oxygenated taxanes254	
N. benthamiana	Taxadiene and taxadiene-5α-ol	The first heterologous synthesis of taxadiene-5α-ol in a plant chassis255	
Tanshinones	S. cerevisiae	Miltiradiene	A high yield of miltiradiene (365 mg/L) was obtained in yeast257	
S. cerevisiae	Miltiradiene	A high yield of miltiradiene (3.5 g/L) was obtained in bioreactor.258	
Hairy roots	Tanshinone	Enhancement of tanshinone content and antioxidant activity by hairy root metabolic engineering for the first time259	
Opioids	S. cerevisiae	Thebaine and hydrocodone	Total biosynthesis of opioids in yeast260	
Cannabinoids	S. cerevisiae	Cannabidiolic acid etc.	Total biosynthesis of cannabinoids in yeast261	
Insulin	E. coli	Insulin A and B chains	Insulin was first produced in E. coli263	
S. cerevisiae	Proinsulin	S. cerevisiae-based expression system is efficient and secret human insulin265	
Recombinant protein vaccines	E. coli	Trumenba®	Recombinant protein vaccine involving E. coli expression system270	
S. cerevisiae	Gardasil	Recombinant protein vaccine involving yeasts expression system271	
CHO	ZF2001	Recombinant protein vaccine involving mammalians cell expression system272	
Sf9 insect cells	Recombinant COVID-19 vaccine	Recombinant protein vaccine involving Insect cells expression system273	
AMPs	E. coli	GKY20	High expression level in E. coli by inclusion body formation275	
E. coli	Melittin etc.	Expression in E. coli using CaM as a carrier protein276	
P. pastoris	Apidaecin	Super heterologous expression and secretion of apidaecin in yeast278	
Valinomycin	Cell-free system	Valinomycin	The first NRP that was fully biosynthesized in vitro using an cell-free system282	
Nisin	Cell-free system	Nisin	Cell-free biosynthesis of nisin was achieved by a CFPS platform284	

Semi-synthetic artemisinin is a successful case of SB-based synthesis. Artemisinin, a highly effective antimalarial drug, is a sesquiterpene lactone, which is naturally obtained from Artemisia annua (Asteraceae).234 Artemisinin and its derivatives also have anticancer,235 anti-inflammation,236 antiviral,237 and anti-SARS-CoV-2 activity.238 Initially, Martin et al. attempted the production of artemisinin precursors in microbial systems; a mevalonate pathway from S. cerevisiae and a synthetic amorpha-4,11-diene synthase (ADS) were heterologously expressed in E. coli, producing amorphadiene (Fig. 6a).239 Synthesis of artemisinic acid in S. cerevisiae was achieved using an engineered mevalonate pathway, amorphadiene synthase, and a novel CYP450 from the eukaryotic origin, all of which could not be perfectly expressed in E. coli; the synthesized artemisinic acid was transported out of the engineered yeast simplifying purification.240 A complete biosynthetic pathway, including a plant dehydrogenase and a second cytochrome, allowed the production of artemisinic acid in engineered S. cerevisiae at a fermentation titer of 25 g/L; singlet oxygen was used to convert artemisinic acid to artemisinin.241 Artemisinin was also produced in two model plants, tobacco (Nicotiana benthamiana) and moss (Physcomitrella patens).242,243

Paclitaxel (taxol), a diterpenoid secondary metabolite derived from the stem bark of Chinese yew (Taxus brevifolia),244 is widely used to treat breast,245 ovarian,246 pancreatic,247 lung,248 and prostate cancers.249 T. brevifolia resources are scarce and have paclitaxel in very low amounts. The chemical synthesis of paclitaxel is complex and costly. Therefore, the industrialized production of paclitaxel by attempted using the tools of SB. Taxadiene, an important intermediate in the paclitaxel biosynthesis pathway, was obtained for the first time by overexpressing DXP synthase, IPP isomerase, GGPP synthase, and taxane synthase genes in E. coli at a titer close to 0.5 mg/L.250 Multiple module metabolic engineering (MMME) in E. coli was used to divide the paclitaxel biosynthetic pathway into an upstream module (containing dxs, idi, ispD, ispF genes) for IPP and DMAPP synthesis and a downstream module (containing GGPPS, TXS genes) for the production of GGPP and taxadiene. The conditions for the optimal balance of the two pathway modules were determined by a systematic multivariate search, resulting in a taxadiene yield of ~1 g/L, which is the highest yield reported so far.251 Since several CYP450s (membrane-bound proteins) are involved in the biosynthesis of paclitaxel, eukaryotic yeasts are more suitable for the heterologous production of paclitaxel and its intermediates. In an S. cerevisiae system, multi-copy chromosomal integration of taxadiene synthase (TXS) harboring fusion solubility tags improved taxadiene titers (Fig. 6b). The effects of the selected promoter, Mg2+ concentration, TXS truncation length, chromosomal gene copy, and cultivation temperature were evaluated; a maximum taxadiene titer of 129 ± 15 mg/L was achieved after strain optimization.252 Recently, a statistical definitive screening design approach combined with the state-of-the-art high-throughput micro-bioreactors resulted in a taxane titer of 229 mg/L.253 A co-cultivation method for the production of oxygenated taxanes was established in a synthetic consortium combining the strengths of E. coli and S. cerevisiae, which produced 33 mg/L of oxygenated taxanes.254 Taxadiene synthase, taxadiene-5α-hydroxylase, and CYP450 reductase were introduced in plant N. benthamian to achieve high-level production of taxadiene and taxadiene-5α-ol using a chloroplastic compartmentalized metabolic engineering strategy combined with enhanced isoprenoid precursors.255 Although many excellent attempts have been made, more efforts are needed to optimize the complete biosynthetic pathway of paclitaxel for its industrial production.

Tanshinones, including tanshinone I, tanshinone IIA, tanshinone IIB, dihydrotanshnone I, and cryptotanshinone, are bioactive diterpenoid compounds produced from the roots of Salvia miltiorrhiza Bunge (Danshen in Chinese), which have a wide range of pharmacological activities including antibacterial, antioxidant, anti-inflammatory, cardiovascular protective, and antineoplastic properties.256 Modularized pathway engineering strategies were applied to create SmCPS and SmKSL fusion proteins with adjacent active sites and fused BTS1 and ERG20 to produce a high yield of miltiradiene (365 mg/L) in S. cerevisiae.257 By increasing the carbon flux toward GGPP and optimizing the gene module of miltiradiene synthases, the production of miltiradiene was further improved in S. cerevisiae, reaching 3.5 g/L in a 5-L bioreactor.258 Hairy roots are also an attractive system for drug production. Three genes, HMGR, DXS, and GGPPS, involved in the biosynthesis pathway for tanshinone were introduced in Salvia miltiorrhiza hairy root for a high-yield production of tanshinone with higher antioxidant activity.259

There have been several efforts for the heterologous production of small-molecule natural drugs based on SB approaches. The full biosynthesis of the opioid compounds thebaine and hydrocodone starting from sugar was engineered in yeast.260 The complete biosynthesis of the major cannabinoids, cannabigerolic acid, Δ9-tetrahydrocannabinolic acid, cannabidiolic acid, Δ9-tetrahydrocannabivarinic acid, and cannabidivarinic acid, starting from the simple sugar galactose was accomplished in S. cerevisiae.261

SB in recombinant protein and nucleic acid production

Protein drugs mainly include recombinant protein drugs, monoclonal antibodies, and recombinant protein vaccines. Compared with small-molecule drugs, protein drugs have high activity, strong specificity, low toxicity, clear biological function, and favorable clinical application.262 In this section, recent examples of recombinant protein and nucleic acid production will be presented; an overview of typical examples is presented in Table 4.

Recombinant human insulin was the first recombinant protein drug. It was produced by the expression of chemically synthesized cDNAs encoding for the insulin A and B chains separately in E. coli and the disulfide bonds were formed under optimal conditions to obtain bioactive insulin.263 A new and more efficient method for human insulin production was developed using a PCR-based cloning strategy that optimized human insulin expression in E. coli using the pET21b expression vector. It eliminated the use of affinity tags, tedious insulin renaturation, inclusion body recovery steps, and the expensive enzymatic cleavage of C-peptide.264 An insulin secretion expression system in S. cerevisiae has been developed, which expresses a cDNA encoding for a proinsulin-like molecule. ThreonineB30 was deleted for the fusion of proinsulin molecule with the S. cerevisiae α-factor prepro-peptide. This was later replaced by human proinsulin C-peptide with a small C-peptide. The purified proinsulin is subsequently converted into human insulin by tryptic transpeptidation.265 Recombinant human insulin has also been successfully produced in transgenic animals and plants, such as mice,266 Arabidopsis thaliana,267 and cucumber.268

The production of monoclonal antibodies (mAbs) has taken tremendous attention in the pharmaceutical industry. A modular synthetic biology approach is proposed to rationally engineer E. coli according to three functional modules to facilitate high-titer production of immunoglobulin G (IgG).269 Bacteria, yeast, insect cells, and mammalian cells are used to express recombinant protein vaccines. Trumenba®, produced in E. coli, was developed by Pfizer and uses two variants of the meningococcal factor H-binding protein as antigens.270 Quadrivalent HPV vaccine, Gardasil, is the first commercially available FDA-licensed HPV vaccine; the L1 gene of four human papillomaviruses is expressed in S. cerevisiae and is used with an aluminum adjuvant.271 Most current COVID-19 recombinant protein vaccines are expressed in mammalian cell culture-based expression systems. ZF2001, consisting of tandemly repeated RBD-dimers and aluminum adjuvants, and the RBD-sc-dimers of MERS-CoV and SARS-CoV-2 both were produced at a high yield in an industry-standard CHO cell system.272 The West China Hospital of Sichuan University has developed a recombinant COVID-19 vaccine using baculovirus as a vector; the RBD region of the SARS-CoV-2 spike protein receptor binding domain is expressed in Sf9 insect cells, which showed effective immunogenicity in phase I and phase II clinical trials.273 According to WHO, there were 54 recombinant COVID-19 protein vaccine candidates in the clinical phase as of June 17, 2022.

Peptide natural products exhibit diverse biological activities, however, the toxicity, limited bioavailability, and difficult mass production hinder their development as therapeutic agents. Natural peptides can be biologically synthesized with the help of SB,274 including recombinant production in bacteria, fungi, and cell-free systems. One way to reduce host toxicity is to produce peptides in E. coli as inclusion bodies. The antimicrobial short peptide (AMP) GKY20 derived from the C-terminus of human thrombin was fused with the C-terminus of Onconase for very high expression as inclusion bodies.275 Fusion proteins also have reduced toxicity for the heterologous expression host. Calmodulin (CaM), a common calcium-sensitive protein in eukaryotes, consists of two independent target binding domains with malleable methionine-rich interaction surfaces that can accommodate many basic and hydrophobic residues.276 CaM can be used as a universal carrier protein to express various types of AMPs in E. coli, such as melittin, fowlicidin-1, tritrpticin, indolicidin, puroindoline A peptide, and human β-defensin 3 (HBD-3). This strategy effectively masks the toxic activity of many AMPs and protects them from degradation during expression and purification.276 Recently, E. coli MSI001, a lethal strain, was isolated from mice; the strain was used for screening bacteria-binding heptapeptides based on an integrative bioinformatics approach, phage display technology, and high-throughput sequencing.277 Yeast is another promising cell factory for the production of peptides. Apidaecins, a series of small and proline-rich antimicrobial peptides act as a defense system against many drug-resistant bacteria. Apidaecin expression in Pichia pastoris was improved after the selection of a mutant strain that limits the loss of the integrated plasmid after induction.278 Additionally, P. pastoris has been used to produce AMPs such as cecropin279 and defensins.280 Cell-free systems provide another solution for the production of natural peptides. Valinomycin is a non-ribosomal peptide with antibacterial, antiviral, and antitumor activities.281 A highly efficient cell-free platform was developed for the rapid, in vitro total biosynthesis of valinomycin with a yield close to 30 mg/L; the cell-free protein synthesis system (CFPS) was coupled with cell-free metabolic engineering system (CFME) by mixing two enzyme-enriched cell lysates to perform the two-stage biosynthesis.282 Other natural peptide products, RiPPs, were also synthesized in cell-free systems. Nisin, a lantipeptide has antibacterial activity and is widely used in the food industry. The cell-free biosynthesis of nisin was achieved by the complete reconstitution of its pathway in a CFPS. The same system can also be used for the genome mining of nisin analogs, screening of mutants, and guiding the overproduction of lanthipeptides in vivo.283 In addition, four different lasso peptides were synthesized using cell-free systems, including known examples such as burhizin, capistruin, and fusilassin and predicted lariat peptides such as ellulassin from Thermobifida halotolerans. This system can rapidly generate and characterize novel lasso peptide variants.284

Nucleic acid vaccines are based on either DNA or mRNA and are amenable to SB design. The target nucleic acid is inserted into human cells, which then produce copies of viral protein. Most of the nucleic acid vaccines against SARS-CoV-2 encode the virus’s spike protein.285 INO-4800, a DNA vaccine candidate targeting the SARS-CoV-2 spike antigen,286 is currently in phase 3 trials. BNT162b2 and mRNR-1273 are the approved mRNA vaccines, both of these LNP-formulated nucleoside-modified mRNA vaccines encode PS2 spike protein of SARS-CoV-2.287 There are 16 DNA-based and 37 RNA-based vaccine candidates of SARS-CoV-2 in the clinical phase, together accounting for about 32% of the total vaccine candidates.

With the advancement in SB, bacteria can also be used as active drugs. An engineered E. coli (EcNL4) was shown to improve gut microbiome and ameliorate colitis in mice.209 A combination therapy of low-dose anti-CD3 with a clinical-grade self-containing Lactococcus lactis (appropriate for human DM application, secreting human proinsulin and interleukin-10) cured 66% of mice with new-onset diabetes.288 A Salmonella typhimurium strain was engineered to secrete Vibrio vulnificus flagellin B (FlaB) in tumor tissues for cancer immunotherapy.289 Virus-based vaccines, such as polio and measles vaccines, are created utilizing an inactivated or weakened pathogen while maintaining the antigenic properties285 Recently, Beijing Sinovac’s inactivated SARS-CoV-2 vaccine has been approved.

Conclusions and prospects

From bacterial-based biosensors and drug development to efficient treatments against pathogens, previously untreatable cancers, and other intractable human pathologies, SB has opened up various possibilities.290 For instance, there are currently seven cancer cell therapies through clinical trials that were approved by the FDA by July 2022.291 Despite these successes, SB-inspired cell engineering in medicine still faces many challenges, such as the lack of available sensors for essential biomarkers. Current microbial diagnostic and theragnostic approaches mostly rely on the existing sensors while numerous proteins with potential applications remain to be fully elucidated.38 Genome editing and manufacturing is a costly and lengthy process. Also, the therapeutic efficacy and technical difficulties limit their clinical applications.292 In addition, precise control of cellular output in engineered cells is very challenging, including the issues of bacteria diffusing to other tissues or being quickly eliminated by the host immune system. CAR-T-cell therapy is hampered by persistent infusion into patients and susceptibility to tumor antigen escape.293 Thus, additional efforts are required to integrate biological, chemical, and mechanical aspects for next-generation cell engineering.

Due to its dynamic multidisciplinary nature comprising different projects, approaches, and definitions, SB is evolving with advancements in biology, pharmacology, materials science, physics, and computational biology.294 The novel synthetic gene circuits combined with “on/off switches”, suicide gene systems, or CRISPR-Cas9 can create more precise control strategies for diagnostics and cell therapeutics. CRISPR-Cas9 significantly eases genome editing at targeted position(s).162 The iCasp9 kill switch has been licensed for more than 20 clinical trials including CAR-T cell and other type cell therapies and may help overcome limitations of currently approved CAR-T-cell therapies.295 In addition, non-biological factors have also been incorporated in SB approaches, such as temperature, light, rays, and nanomaterials. The integration of chemical biotechnology such as nanomaterial-coated bacteria provides tremendous promise for efficient transport, long-term storage, and spatial-temporal control in host.26 Gujrati et al. engineered bacteria to secrete melanin-containing OMVs with high photothermal conversion efficiency for photoacoustic imaging and photothermal therapy of 4T1 breast tumor.296 Moreover, the tools of computational biology such as machine learning can change the approach of SB by improving the search for biological components, optimizing design, and reforming/creating novel elements.

Taken together, recent advances in SB-related cellular diagnostics and therapeutics can significantly transform healthcare paradigms. Currently approved CAR-T therapies and upcoming clinical trials of other engineered cell therapies also inspire the rapid expansion of SB. SB-based biofactories can contribute to the screening and development of new and affordable medicines, including recombinant vaccines. In light of this, SB-inspired cell engineering will enter a new perspective and expand its application for various disease treatments.

Acknowledgements

This work was funded by the National Natural Science Foundation of China (Grant No. 81871615).

Author contributions

RB and HW conceived, supervised, and revised the paper; NZ, YS, and XX participated in different parts of writing and organized figures and formatted the paper; ZZ, CD, and CN collected related literature.

Competing interests

The authors declare no competing interests.

These authors contributed equally: Ninglin Zhao, Yingjie Song, Xiangqian Xie.
==== Refs
References

1. Cameron DE Bashor CJ Collins JJ A brief history of synthetic biology Nat. Rev. Microbiol. 2014 12 381 390 24686414
Cameron, D. E., Bashor, C. J. & Collins, J. J. A brief history of synthetic biology. Nat. Rev. Microbiol. 12, 381–390 (2014).24686414
2. Shapira P Kwon S Youtie J Tracking the emergence of synthetic biology Scientometrics 2017 112 1439 1469 28804177
Shapira, P., Kwon, S. & Youtie, J. Tracking the emergence of synthetic biology. Scientometrics 112, 1439–1469 (2017).28804177
3. Meng F Ellis T The second decade of synthetic biology: 2010–2020 Nat. Commun. 2020 11 5174 33057059
Meng, F. & Ellis, T. The second decade of synthetic biology: 2010–2020. Nat. Commun. 11, 5174 (2020).33057059
4. Xie M Haellman V Fussenegger M Synthetic biology-application-oriented cell engineering Curr. Opin. Biotechnol. 2016 40 139 148 27135809
Xie, M., Haellman, V. & Fussenegger, M. Synthetic biology-application-oriented cell engineering. Curr. Opin. Biotechnol. 40, 139–148 (2016).27135809
5. Schwille P Diez S Synthetic biology of minimal systems Crit. Rev. Biochem. Mol. Biol. 2009 44 223 242 19635039
Schwille, P. & Diez, S. Synthetic biology of minimal systems. Crit. Rev. Biochem. Mol. Biol. 44, 223–242 (2009).19635039
6. de Lorenzo V Krasnogor N Schmidt M For the sake of the Bioeconomy: define what a synthetic biology chassis is! N. Biotechnol. 2021 60 44 51 32889152
de Lorenzo, V., Krasnogor, N. & Schmidt, M. For the sake of the Bioeconomy: define what a synthetic biology chassis is! N. Biotechnol. 60, 44–51 (2021).32889152
7. Polizzi KM What is synthetic biology? Methods Mol. Biol. 2013 1073 3 6 23996434
Polizzi, K. M. What is synthetic biology? Methods Mol. Biol. 1073, 3–6 (2013).23996434
8. Purnick PE Weiss R The second wave of synthetic biology: from modules to systems Nat. Rev. Mol. Cell Biol. 2009 10 410 422 19461664
Purnick, P. E. & Weiss, R. The second wave of synthetic biology: from modules to systems. Nat. Rev. Mol. Cell Biol. 10, 410–422 (2009).19461664
9. Chen YY Galloway KE Smolke CD Synthetic biology: advancing biological frontiers by building synthetic systems Genome Biol. 2012 13 240 22348749
Chen, Y. Y., Galloway, K. E. & Smolke, C. D. Synthetic biology: advancing biological frontiers by building synthetic systems. Genome Biol. 13, 240 (2012).22348749
10. Singh V Recent advancements in synthetic biology: current status and challenges Gene 2014 535 1 11 24269673
Singh, V. Recent advancements in synthetic biology: current status and challenges. Gene 535, 1–11 (2014).24269673
11. Khalil AS Collins JJ Synthetic biology: applications come of age Nat. Rev. Genet. 2010 11 367 379 20395970
Khalil, A. S. & Collins, J. J. Synthetic biology: applications come of age. Nat. Rev. Genet. 11, 367–379 (2010).20395970
12. Ruder WC Lu T Collins JJ Synthetic biology moving into the clinic Science 2011 333 1248 1252 21885773
Ruder, W. C., Lu, T. & Collins, J. J. Synthetic biology moving into the clinic. Science 333, 1248–1252 (2011).21885773
13. Wang F Zhao D Qi LS Application of genome engineering in medical synthetic biology Sheng Wu Gong. Cheng Xue Bao. 2017 33 422 435 28941341
Wang, F., Zhao, D. & Qi, L. S. Application of genome engineering in medical synthetic biology. Sheng Wu Gong. Cheng Xue Bao. 33, 422–435 (2017).28941341
14. Courbet A Renard E Molina F Bringing next-generation diagnostics to the clinic through synthetic biology EMBO Mol. Med. 2016 8 987 991 27402339
Courbet, A., Renard, E. & Molina, F. Bringing next-generation diagnostics to the clinic through synthetic biology. EMBO Mol. Med. 8, 987–991 (2016).27402339
15. Cheng AA Lu TK Synthetic biology: an emerging engineering discipline Annu. Rev. Biomed. Eng. 2012 14 155 178 22577777
Cheng, A. A. & Lu, T. K. Synthetic biology: an emerging engineering discipline. Annu. Rev. Biomed. Eng. 14, 155–178 (2012).22577777
16. Abil Z Xiong X Zhao H Synthetic biology for therapeutic applications Mol. Pharm. 2015 12 322 331 25098838
Abil, Z., Xiong, X. & Zhao, H. Synthetic biology for therapeutic applications. Mol. Pharm. 12, 322–331 (2015).25098838
17. Chien T Doshi A Danino T Advances in bacterial cancer therapies using synthetic biology Curr. Opin. Syst. Biol. 2017 5 1 8 29881788
Chien, T., Doshi, A. & Danino, T. Advances in bacterial cancer therapies using synthetic biology. Curr. Opin. Syst. Biol. 5, 1–8 (2017).29881788
18. Bober JR Beisel CL Nair NU Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications Annu. Rev. Biomed. Eng. 2018 20 277 300 29528686
Bober, J. R., Beisel, C. L. & Nair, N. U. Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications. Annu. Rev. Biomed. Eng. 20, 277–300 (2018).29528686
19. Lemire S Yehl KM Lu TK Phage-based applications in synthetic biology Annu. Rev. Virol. 2018 5 453 476 30001182
Lemire, S., Yehl, K. M. & Lu, T. K. Phage-based applications in synthetic biology. Annu. Rev. Virol. 5, 453–476 (2018).30001182
20. Ozdemir T Fedorec AJH Danino T Barnes CP Synthetic biology and engineered live biotherapeutics: toward increasing system complexity Cell Syst. 2018 7 5 16 30048620
Ozdemir, T., Fedorec, A. J. H., Danino, T. & Barnes, C. P. Synthetic biology and engineered live biotherapeutics: toward increasing system complexity. Cell Syst. 7, 5–16 (2018).30048620
21. Wu MR Jusiak B Lu TK Engineering advanced cancer therapies with synthetic biology Nat. Rev. Cancer 2019 19 187 195 30837696
Wu, M. R., Jusiak, B. & Lu, T. K. Engineering advanced cancer therapies with synthetic biology. Nat. Rev. Cancer 19, 187–195 (2019).30837696
22. Romanowski S Eustaquio AS Synthetic biology for natural product drug production and engineering Curr. Opin. Chem. Biol. 2020 58 137 145 33130520
Romanowski, S. & Eustaquio, A. S. Synthetic biology for natural product drug production and engineering. Curr. Opin. Chem. Biol. 58, 137–145 (2020).33130520
23. Cubillos-Ruiz A Engineering living therapeutics with synthetic biology Nat. Rev. Drug Discov. 2021 20 941 960 34616030
Cubillos-Ruiz, A. et al. Engineering living therapeutics with synthetic biology. Nat. Rev. Drug Discov. 20, 941–960 (2021).34616030
24. Lenneman BR Enhancing phage therapy through synthetic biology and genome engineering Curr. Opin. Biotechnol. 2021 68 151 159 33310655
Lenneman, B. R. et al. Enhancing phage therapy through synthetic biology and genome engineering. Curr. Opin. Biotechnol. 68, 151–159 (2021).33310655
25. McNerney MP Theranostic cells: emerging clinical applications of synthetic biology Nat. Rev. Genet. 2021 22 730 746 34234299
McNerney, M. P. et al. Theranostic cells: emerging clinical applications of synthetic biology. Nat. Rev. Genet. 22, 730–746 (2021).34234299
26. Tan X Letendre JH Collins JJ Wong WW Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics Cell 2021 184 881 898 33571426
Tan, X., Letendre, J. H., Collins, J. J. & Wong, W. W. Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. Cell 184, 881–898 (2021).33571426
27. Amrofell MB Rottinghaus AG Moon TS Engineering microbial diagnostics and therapeutics with smart control Curr. Opin. Biotechnol. 2020 66 11 17 32563763
Amrofell, M. B., Rottinghaus, A. G. & Moon, T. S. Engineering microbial diagnostics and therapeutics with smart control. Curr. Opin. Biotechnol. 66, 11–17 (2020).32563763
28. Slomovic S Pardee K Collins JJ Synthetic biology devices for in vitro and in vivo diagnostics Proc. Natl Acad. Sci. USA 2015 112 14429 14435 26598662
Slomovic, S., Pardee, K. & Collins, J. J. Synthetic biology devices for in vitro and in vivo diagnostics. Proc. Natl Acad. Sci. USA 112, 14429–14435 (2015).26598662
29. Gui Q The application of whole cell-based biosensors for use in environmental analysis and in medical diagnostics Sensors 2017 17 1623 28703749
Gui, Q. et al. The application of whole cell-based biosensors for use in environmental analysis and in medical diagnostics. Sensors 17, 1623 (2017).28703749
30. Ali AA Altemimi AB Alhelfi N Ibrahim SA Application of biosensors for detection of pathogenic food bacteria: a review Biosensors 2020 10 58 32486225
Ali, A. A., Altemimi, A. B., Alhelfi, N. & Ibrahim, S. A. Application of biosensors for detection of pathogenic food bacteria: a review. Biosensors 10, 58 (2020).32486225
31. Su L Jia W Hou C Lei Y Microbial biosensors: a review Biosens. Bioelectron. 2011 26 1788 1799 20951023
Su, L., Jia, W., Hou, C. & Lei, Y. Microbial biosensors: a review. Biosens. Bioelectron. 26, 1788–1799 (2011).20951023
32. van der Meer JR Belkin S Where microbiology meets microengineering: design and applications of reporter bacteria Nat. Rev. Microbiol. 2010 8 511 522 20514043
van der Meer, J. R. & Belkin, S. Where microbiology meets microengineering: design and applications of reporter bacteria. Nat. Rev. Microbiol. 8, 511–522 (2010).20514043
33. Liu L Bilal M Duan X Iqbal HMN Mitigation of environmental pollution by genetically engineered bacteria—current challenges and future perspectives Sci. Total Environ. 2019 667 444 454 30833243
Liu, L., Bilal, M., Duan, X. & Iqbal, H. M. N. Mitigation of environmental pollution by genetically engineered bacteria—current challenges and future perspectives. Sci. Total Environ. 667, 444–454 (2019).30833243
34. Hicks M Bachmann TT Wang B Synthetic biology enables programmable cell-based biosensors Chemphyschem 2020 21 132 144 31585026
Hicks, M., Bachmann, T. T. & Wang, B. Synthetic biology enables programmable cell-based biosensors. Chemphyschem 21, 132–144 (2020).31585026
35. Soleimany AP Bhatia SN Activity-based diagnostics: an emerging paradigm for disease detection and monitoring Trends Mol. Med. 2020 26 450 468 32359477
Soleimany, A. P. & Bhatia, S. N. Activity-based diagnostics: an emerging paradigm for disease detection and monitoring. Trends Mol. Med. 26, 450–468 (2020).32359477
36. Wei TY Cheng CM Synthetic biology-based point-of-care diagnostics for infectious disease Cell Chem. Biol. 2016 23 1056 1066 27662252
Wei, T. Y. & Cheng, C. M. Synthetic biology-based point-of-care diagnostics for infectious disease. Cell Chem. Biol. 23, 1056–1066 (2016).27662252
37. McNerney MP Dynamic and tunable metabolite control for robust minimal-equipment assessment of serum zinc Nat. Commun. 2019 10 5514 31797936
McNerney, M. P. et al. Dynamic and tunable metabolite control for robust minimal-equipment assessment of serum zinc. Nat. Commun. 10, 5514 (2019).31797936
38. Courbet A Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates Sci. Transl. Med. 2015 7 289ra283
Courbet, A. et al. Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates. Sci. Transl. Med. 7, 289ra283 (2015).
39. Hooshangi S Bentley WE From unicellular properties to multicellular behavior: bacteria quorum sensing circuitry and applications Curr. Opin. Biotechnol. 2008 19 550 555 18977301
Hooshangi, S. & Bentley, W. E. From unicellular properties to multicellular behavior: bacteria quorum sensing circuitry and applications. Curr. Opin. Biotechnol. 19, 550–555 (2008).18977301
40. Kumari A Pasini P Daunert S Detection of bacterial quorum sensing N-acyl homoserine lactones in clinical samples Anal. Bioanal. Chem. 2008 391 1619 1627 18408921
Kumari, A., Pasini, P. & Daunert, S. Detection of bacterial quorum sensing N-acyl homoserine lactones in clinical samples. Anal. Bioanal. Chem. 391, 1619–1627 (2008).18408921
41. Capatina D Analytical methods for the characterization and diagnosis of infection with Pseudomonas aeruginosa: a critical review Anal. Chim. Acta 2022 1204 339696 35397917
Capatina, D. et al. Analytical methods for the characterization and diagnosis of infection with Pseudomonas aeruginosa: a critical review. Anal. Chim. Acta 1204, 339696 (2022).35397917
42. Li Y Advanced detection and sensing strategies of Pseudomonas aeruginosa and quorum sensing biomarkers: a review Talanta 2022 240 123210 35026633
Li, Y. et al. Advanced detection and sensing strategies of Pseudomonas aeruginosa and quorum sensing biomarkers: a review. Talanta 240, 123210 (2022).35026633
43. Stephens K Bentley WE Synthetic biology for manipulating quorum sensing in microbial consortia Trends Microbiol. 2020 28 633 643 32340782
Stephens, K. & Bentley, W. E. Synthetic biology for manipulating quorum sensing in microbial consortia. Trends Microbiol. 28, 633–643 (2020).32340782
44. Mao N Cubillos-Ruiz A Cameron DE Collins JJ Probiotic strains detect and suppress cholera in mice Sci. Transl. Med. 2018 10 eaao2586 29899022
Mao, N., Cubillos-Ruiz, A., Cameron, D. E. & Collins, J. J. Probiotic strains detect and suppress cholera in mice. Sci. Transl. Med. 10, eaao2586 (2018).29899022
45. Lubkowicz D Reprogramming probiotic Lactobacillus reuteri as a biosensor for Staphylococcus aureus derived AIP-I detection ACS Synth. Biol. 2018 7 1229 1237 29652493
Lubkowicz, D. et al. Reprogramming probiotic Lactobacillus reuteri as a biosensor for Staphylococcus aureus derived AIP-I detection. ACS Synth. Biol. 7, 1229–1237 (2018).29652493
46. Beier D Gross R Regulation of bacterial virulence by two-component systems Curr. Opin. Microbiol. 2006 9 143 152 16481212
Beier, D. & Gross, R. Regulation of bacterial virulence by two-component systems. Curr. Opin. Microbiol. 9, 143–152 (2006).16481212
47. Lazar JT Tabor JJ Bacterial two-component systems as sensors for synthetic biology applications Curr. Opin. Syst. Biol. 2021 28 100398 34917859
Lazar, J. T. & Tabor, J. J. Bacterial two-component systems as sensors for synthetic biology applications. Curr. Opin. Syst. Biol. 28, 100398 (2021).34917859
48. Holowko MB Wang H Jayaraman P Poh CL Biosensing Vibrio cholerae with genetically engineered Escherichia coli ACS Synth. Biol. 2016 5 1275 1283 27529184
Holowko, M. B., Wang, H., Jayaraman, P. & Poh, C. L. Biosensing Vibrio cholerae with genetically engineered Escherichia coli . ACS Synth. Biol. 5, 1275–1283 (2016).27529184
49. Daeffler KN Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation Mol. Syst. Biol. 2017 13 923 28373240
Daeffler, K. N. et al. Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation. Mol. Syst. Biol. 13, 923 (2017).28373240
50. Riglar DT Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation Nat. Biotechnol. 2017 35 653 658 28553941
Riglar, D. T. et al. Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat. Biotechnol. 35, 653–658 (2017).28553941
51. Woo SG A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing Biosens. Bioelectron. 2020 168 112523 32871497
Woo, S. G. et al. A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing. Biosens. Bioelectron. 168, 112523 (2020).32871497
52. Danino T Programmable probiotics for detection of cancer in urine Sci. Transl. Med. 2015 7 289ra284
Danino, T. et al. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med. 7, 289ra284 (2015).
53. Mimee M An ingestible bacterial-electronic system to monitor gastrointestinal health Science 2018 360 915 918 29798884
Mimee, M. et al. An ingestible bacterial-electronic system to monitor gastrointestinal health. Science 360, 915–918 (2018).29798884
54. Chan C Measurement of biodegradable substances using the salt-tolerant yeast Arxula adeninivorans for a microbial sensor immobilized with poly(carbamoyl) sulfonate (PCS) Part I: construction and characterization of the microbial sensor Biosens. Bioelectron. 1999 14 131 138 10101835
Chan, C. et al. Measurement of biodegradable substances using the salt-tolerant yeast Arxula adeninivorans for a microbial sensor immobilized with poly(carbamoyl) sulfonate (PCS) Part I: construction and characterization of the microbial sensor. Biosens. Bioelectron. 14, 131–138 (1999).10101835
55. Shimomura-Shimizu M Karube I Yeast based sensors Adv. Biochem. Eng. Biotechnol. 2010 117 1 19 20087724
Shimomura-Shimizu, M. & Karube, I. Yeast based sensors. Adv. Biochem. Eng. Biotechnol. 117, 1–19 (2010).20087724
56. Sun L Liao K Wang D Effects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicans PLoS ONE 2015 10 e0117695 25710475
Sun, L., Liao, K. & Wang, D. Effects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicans. PLoS ONE 10, e0117695 (2015).25710475
57. Ostrov N A modular yeast biosensor for low-cost point-of-care pathogen detection Sci. Adv. 2017 3 e1603221 28782007
Ostrov, N. et al. A modular yeast biosensor for low-cost point-of-care pathogen detection. Sci. Adv. 3, e1603221 (2017).28782007
58. Jacobson KA New paradigms in GPCR drug discovery Biochem. Pharmacol. 2015 98 541 555 26265138
Jacobson, K. A. New paradigms in GPCR drug discovery. Biochem. Pharmacol. 98, 541–555 (2015).26265138
59. Miao Y McCammon JA G-protein coupled receptors: advances in simulation and drug discovery Curr. Opin. Struct. Biol. 2016 41 83 89 27344006
Miao, Y. & McCammon, J. A. G-protein coupled receptors: advances in simulation and drug discovery. Curr. Opin. Struct. Biol. 41, 83–89 (2016).27344006
60. Smutok OV d-lactate-selective amperometric biosensor based on the cell debris of the recombinant yeast Hansenula polymorpha Talanta 2014 125 227 232 24840438
Smutok, O. V. et al. d-lactate-selective amperometric biosensor based on the cell debris of the recombinant yeast Hansenula polymorpha. Talanta 125, 227–232 (2014).24840438
61. Karkovska M Smutok O Stasyuk N Gonchar M L-lactate-selective microbial sensor based on flavocytochrome b2-enriched yeast cells using recombinant and nanotechnology approaches Talanta 2015 144 1195 1200 26452947
Karkovska, M., Smutok, O., Stasyuk, N. & Gonchar, M. L-lactate-selective microbial sensor based on flavocytochrome b2-enriched yeast cells using recombinant and nanotechnology approaches. Talanta 144, 1195–1200 (2015).26452947
62. Miller RA “Scentsor”: a whole-cell yeast biosensor with an olfactory reporter for low-cost and equipment-free detection of pharmaceuticals ACS Sens. 2020 5 3025 3030 32964706
Miller, R. A. et al. “Scentsor”: a whole-cell yeast biosensor with an olfactory reporter for low-cost and equipment-free detection of pharmaceuticals. ACS Sens. 5, 3025–3030 (2020).32964706
63. Miller RA Development of a paper-immobilized yeast biosensor for the detection of physiological concentrations of doxycycline in technology-limited settings Anal. Methods 2020 12 2123 2132
Miller, R. A. et al. Development of a paper-immobilized yeast biosensor for the detection of physiological concentrations of doxycycline in technology-limited settings. Anal. Methods 12, 2123–2132 (2020).
64. Lienert F Lohmueller JJ Garg A Silver PA Synthetic biology in mammalian cells: next generation research tools and therapeutics Nat. Rev. Mol. Cell Biol. 2014 15 95 107 24434884
Lienert, F., Lohmueller, J. J., Garg, A. & Silver, P. A. Synthetic biology in mammalian cells: next generation research tools and therapeutics. Nat. Rev. Mol. Cell Biol. 15, 95–107 (2014).24434884
65. Auslander D A designer cell-based histamine-specific human allergy profiler Nat. Commun. 2014 5 4408 25093291
Auslander, D. et al. A designer cell-based histamine-specific human allergy profiler. Nat. Commun. 5, 4408 (2014).25093291
66. Tastanova A Synthetic biology-based cellular biomedical tattoo for detection of hypercalcemia associated with cancer Sci. Transl. Med. 2018 10 eaap8562 29669854
Tastanova, A. et al. Synthetic biology-based cellular biomedical tattoo for detection of hypercalcemia associated with cancer. Sci. Transl. Med. 10, eaap8562 (2018).29669854
67. Banerjee P Bhunia AK Mammalian cell-based biosensors for pathogens and toxins Trends Biotechnol. 2009 27 179 188 19187988
Banerjee, P. & Bhunia, A. K. Mammalian cell-based biosensors for pathogens and toxins. Trends Biotechnol. 27, 179–188 (2009).19187988
68. Menge C Molecular biology of Escherichia coli shiga toxins’ effects on mammalian cells Toxins 2020 12 345 32456125
Menge, C. Molecular biology of Escherichia coli shiga toxins’ effects on mammalian cells. Toxins 12, 345 (2020).32456125
69. To CZ Bhunia AK Three dimensional vero cell-platform for rapid and sensitive screening of shiga-toxin producing Escherichia coli Front. Microbiol. 2019 10 949 31134009
To, C. Z. & Bhunia, A. K. Three dimensional vero cell-platform for rapid and sensitive screening of shiga-toxin producing Escherichia coli. Front. Microbiol. 10, 949 (2019).31134009
70. Carlos D Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE-mediated reaction Eur. J. Immunol. 2006 36 1494 1503 16703563
Carlos, D. et al. Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE-mediated reaction. Eur. J. Immunol. 36, 1494–1503 (2006).16703563
71. Jiang D A novel electrochemical mast cell-based paper biosensor for the rapid detection of milk allergen casein Biosens. Bioelectron. 2019 130 299 306 30776617
Jiang, D. et al. A novel electrochemical mast cell-based paper biosensor for the rapid detection of milk allergen casein. Biosens. Bioelectron. 130, 299–306 (2019).30776617
72. Schofield DA Sharp NJ Westwater C Phage-based platforms for the clinical detection of human bacterial pathogens Bacteriophage 2012 2 105 283 23050221
Schofield, D. A., Sharp, N. J. & Westwater, C. Phage-based platforms for the clinical detection of human bacterial pathogens. Bacteriophage 2, 105–283 (2012).23050221
73. Lu TK Bowers J Koeris MS Advancing bacteriophage-based microbial diagnostics with synthetic biology Trends Biotechnol. 2013 31 325 327 23608522
Lu, T. K., Bowers, J. & Koeris, M. S. Advancing bacteriophage-based microbial diagnostics with synthetic biology. Trends Biotechnol. 31, 325–327 (2013).23608522
74. Sharp NJ Vandamm JP Molineux IJ Schofield DA Rapid detection of Bacillus anthracis in complex food matrices using phage-mediated bioluminescence J. Food Prot. 2015 78 963 968 25951391
Sharp, N. J., Vandamm, J. P., Molineux, I. J. & Schofield, D. A. Rapid detection of Bacillus anthracis in complex food matrices using phage-mediated bioluminescence. J. Food Prot. 78, 963–968 (2015).25951391
75. Sharp NJ Molineux IJ Page MA Schofield DA Rapid detection of viable Bacillus anthracis spores in environmental samples by using engineered reporter phages Appl. Environ. Microbiol. 2016 82 2380 2387 26873316
Sharp, N. J., Molineux, I. J., Page, M. A. & Schofield, D. A. Rapid detection of viable Bacillus anthracis spores in environmental samples by using engineered reporter phages. Appl. Environ. Microbiol. 82, 2380–2387 (2016).26873316
76. Peng Y Application of the VPp1 bacteriophage combined with a coupled enzyme system in the rapid detection of Vibrio parahaemolyticus J. Microbiol. Methods 2014 98 99 104 24440165
Peng, Y. et al. Application of the VPp1 bacteriophage combined with a coupled enzyme system in the rapid detection of Vibrio parahaemolyticus. J. Microbiol. Methods 98, 99–104 (2014).24440165
77. Kim S Kim M Ryu S Development of an engineered bioluminescent reporter phage for the sensitive detection of viable Salmonella typhimurium Anal. Chem. 2014 86 5858 5864 24806327
Kim, S., Kim, M. & Ryu, S. Development of an engineered bioluminescent reporter phage for the sensitive detection of viable Salmonella typhimurium. Anal. Chem. 86, 5858–5864 (2014).24806327
78. Oosterik LH Bioluminescent avian pathogenic Escherichia coli for monitoring colibacillosis in experimentally infected chickens Vet. J. 2016 216 87 92 27687932
Oosterik, L. H. et al. Bioluminescent avian pathogenic Escherichia coli for monitoring colibacillosis in experimentally infected chickens. Vet. J. 216, 87–92 (2016).27687932
79. Kim J Kim M Kim S Ryu S Sensitive detection of viable Escherichia coli O157:H7 from foods using a luciferase-reporter phage phiV10lux Int. J. Food Microbiol. 2017 254 11 17 28511109
Kim, J., Kim, M., Kim, S. & Ryu, S. Sensitive detection of viable Escherichia coli O157:H7 from foods using a luciferase-reporter phage phiV10lux. Int. J. Food Microbiol. 254, 11–17 (2017).28511109
80. Rees JC Pierce CL Schieltz DM Barr JR Simultaneous identification and susceptibility determination to multiple antibiotics of Staphylococcus aureus by bacteriophage amplification detection combined with mass spectrometry Anal. Chem. 2015 87 6769 6777 26016659
Rees, J. C., Pierce, C. L., Schieltz, D. M. & Barr, J. R. Simultaneous identification and susceptibility determination to multiple antibiotics of Staphylococcus aureus by bacteriophage amplification detection combined with mass spectrometry. Anal. Chem. 87, 6769–6777 (2015).26016659
81. Vandamm JP Rapid detection and simultaneous antibiotic susceptibility analysis of Yersinia pestis directly from clinical specimens by use of reporter phage J. Clin. Microbiol. 2014 52 2998 3003 24920765
Vandamm, J. P. et al. Rapid detection and simultaneous antibiotic susceptibility analysis of Yersinia pestis directly from clinical specimens by use of reporter phage. J. Clin. Microbiol. 52, 2998–3003 (2014).24920765
82. Rondon L Fluoromycobacteriophages can detect viable Mycobacterium tuberculosis and determine phenotypic rifampicin resistance in 3-5 days from sputum collection Front. Microbiol. 2018 9 1471 30026735
Rondon, L. et al. Fluoromycobacteriophages can detect viable Mycobacterium tuberculosis and determine phenotypic rifampicin resistance in 3-5 days from sputum collection. Front. Microbiol. 9, 1471 (2018).30026735
83. Meile S Engineered reporter phages for rapid bioluminescence-based detection and differentiation of viable listeria cells Appl. Environ. Microbiol. 2020 86 e00442 00420 32245761
Meile, S. et al. Engineered reporter phages for rapid bioluminescence-based detection and differentiation of viable listeria cells. Appl. Environ. Microbiol. 86, e00442–00420 (2020).32245761
84. Xu J Chau Y Lee YK Phage-based electrochemical sensors: a review Micromachines 2019 10 855 31817610
Xu, J., Chau, Y. & Lee, Y. K. Phage-based electrochemical sensors: a review. Micromachines 10, 855 (2019).31817610
85. Niyomdecha S Phage-based capacitive biosensor for Salmonella detection Talanta 2018 188 658 664 30029427
Niyomdecha, S. et al. Phage-based capacitive biosensor for Salmonella detection. Talanta 188, 658–664 (2018).30029427
86. Farooq U High-density phage particles immobilization in surface-modified bacterial cellulose for ultra-sensitive and selective electrochemical detection of Staphylococcus aureus Biosens. Bioelectron. 2020 157 112163 32250935
Farooq, U. et al. High-density phage particles immobilization in surface-modified bacterial cellulose for ultra-sensitive and selective electrochemical detection of Staphylococcus aureus. Biosens. Bioelectron. 157, 112163 (2020).32250935
87. Shin JH Electrochemical detection of caspase-3 based on a chemically modified M13 phage virus Bioelectrochemistry 2022 145 108090 35240465
Shin, J. H. et al. Electrochemical detection of caspase-3 based on a chemically modified M13 phage virus. Bioelectrochemistry 145, 108090 (2022).35240465
88. Hu L Study on the conduction analysis and blocking intervention scheme of emotional disorders between cancer patients and their families Comput. Math. Methods Med. 2022 2022 4820090 35509855
Hu, L. et al. Study on the conduction analysis and blocking intervention scheme of emotional disorders between cancer patients and their families. Comput. Math. Methods Med. 2022, 4820090 (2022).35509855
89. Qiu X Zhang K Zhang Y Sun L Benefit finding and related factors of patients with early-stage cancer in China Int. J. Environ. Res. Public Health 2022 19 4284 35409965
Qiu, X., Zhang, K., Zhang, Y. & Sun, L. Benefit finding and related factors of patients with early-stage cancer in China. Int. J. Environ. Res. Public Health 19, 4284 (2022).35409965
90. Cao W Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 Chin. Med. J. 2021 134 783 791 33734139
Cao, W. et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin. Med. J. 134, 783–791 (2021).33734139
91. Lu D-Y Drug combination in clinical cancer treatments Rev. Recent Clin. Trials 2017 12 202 211 28782482
Lu, D.-Y. et al. Drug combination in clinical cancer treatments. Rev. Recent Clin. Trials 12, 202–211 (2017).28782482
92. Bell Gorrod H A review of survival analysis methods used in NICE technology appraisals of cancer treatments: consistency, limitations, and areas for improvement Med Decis. Mak. 2019 39 899 909
Bell Gorrod, H. et al. A review of survival analysis methods used in NICE technology appraisals of cancer treatments: consistency, limitations, and areas for improvement. Med Decis. Mak. 39, 899–909 (2019).
93. Wilt TJ Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer Ann. Intern. Med. 2008 148 435 448 18252677
Wilt, T. J. et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann. Intern. Med. 148, 435–448 (2008).18252677
94. Marin JJ Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours Anticancer Agents Med. Chem. 2009 9 162 184 19199863
Marin, J. J. et al. Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours. Anticancer Agents Med. Chem. 9, 162–184 (2009).19199863
95. Kalos M June CH Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology Immunity 2013 39 49 60 23890063
Kalos, M. & June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49–60 (2013).23890063
96. Choe JH Williams JZ Lim WA Engineering T cells to treat cancer: the convergence of immuno-oncology and synthetic biology Annu. Rev. Cancer Biol. 2020 4 121 139
Choe, J. H., Williams, J. Z. & Lim, W. A. Engineering T cells to treat cancer: the convergence of immuno-oncology and synthetic biology. Annu. Rev. Cancer Biol. 4, 121–139 (2020).
97. Chakravarti D Wong WW Synthetic biology in cell-based cancer immunotherapy Trends Biotechnol. 2015 33 449 461 26088008
Chakravarti, D. & Wong, W. W. Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol. 33, 449–461 (2015).26088008
98. Jain RK Forbes NS Can engineered bacteria help control cancer? Proc. Natl Acad. Sci. USA 2001 98 14748 14750 11752416
Jain, R. K. & Forbes, N. S. Can engineered bacteria help control cancer? Proc. Natl Acad. Sci. USA 98, 14748–14750 (2001).11752416
99. Anderson JC Clarke EJ Arkin AP Voigt CA Environmentally controlled invasion of cancer cells by engineered bacteria J. Mol. Biol. 2006 355 619 627 16330045
Anderson, J. C., Clarke, E. J., Arkin, A. P. & Voigt, C. A. Environmentally controlled invasion of cancer cells by engineered bacteria. J. Mol. Biol. 355, 619–627 (2006).16330045
100. Lee C-H Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives Appl. Microbiol. Biotechnol. 2012 93 517 523 22120621
Lee, C.-H. Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. Appl. Microbiol. Biotechnol. 93, 517–523 (2012).22120621
101. Yin T Engineering bacteria and bionic bacterial derivatives with nanoparticles for cancer therapy Small 2022 18 2104643
Yin, T. et al. Engineering bacteria and bionic bacterial derivatives with nanoparticles for cancer therapy. Small 18, 2104643 (2022).
102. Forbes NS Engineering the perfect (bacterial) cancer therapy Nat. Rev. Cancer 2010 10 785 794 20944664
Forbes, N. S. Engineering the perfect (bacterial) cancer therapy. Nat. Rev. Cancer 10, 785–794 (2010).20944664
103. Mengesha A Potential and limitations of bacterial-mediated cancer therapy Front. Biosci. 2007 12 3880 3891 17485344
Mengesha, A. et al. Potential and limitations of bacterial-mediated cancer therapy. Front. Biosci. 12, 3880–3891 (2007).17485344
104. Weerakkody LR Witharana C The role of bacterial toxins and spores in cancer therapy Life Sci. 2019 235 116839 31499068
Weerakkody, L. R. & Witharana, C. The role of bacterial toxins and spores in cancer therapy. Life Sci. 235, 116839 (2019).31499068
105. Li Z Chemically and biologically engineered bacteria‐based delivery systems for emerging diagnosis and advanced therapy Adv. Mater. 2021 33 2102580
Li, Z. et al. Chemically and biologically engineered bacteria‐based delivery systems for emerging diagnosis and advanced therapy. Adv. Mater. 33, 2102580 (2021).
106. Wiemann B Starnes CO Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective Pharmacol. Ther. 1994 64 529 564 7724661
Wiemann, B. & Starnes, C. O. Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 64, 529–564 (1994).7724661
107. McCarthy EF The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas Iowa Orthop. J. 2006 26 154 16789469
McCarthy, E. F. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 26, 154 (2006).16789469
108. Guerra L Cortes-Bratti X Guidi R Frisan T The biology of the cytolethal distending toxins Toxins 2011 3 172 190 22069704
Guerra, L., Cortes-Bratti, X., Guidi, R. & Frisan, T. The biology of the cytolethal distending toxins. Toxins 3, 172–190 (2011).22069704
109. Taieb F Nougayrède J-P Oswald E Cycle inhibiting factors (cifs): cyclomodulins that usurp the ubiquitin-dependent degradation pathway of host cells Toxins 2011 3 356 368 22069713
Taieb, F., Nougayrède, J.-P. & Oswald, E. Cycle inhibiting factors (cifs): cyclomodulins that usurp the ubiquitin-dependent degradation pathway of host cells. Toxins 3, 356–368 (2011).22069713
110. Goldufsky J Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines J. Med. Microbiol. 2015 64 164 25627204
Goldufsky, J. et al. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J. Med. Microbiol. 64, 164 (2015).25627204
111. Balachandran P The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence J. Clin. Investig. 2007 117 419 427 17235393
Balachandran, P. et al. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. J. Clin. Investig. 117, 419–427 (2007).17235393
112. Shafikhani SH Morales C Engel J The Pseudomonas aeruginosa type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells Cell. Microbiol. 2008 10 994 1007 18053004
Shafikhani, S. H., Morales, C. & Engel, J. The Pseudomonas aeruginosa type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells. Cell. Microbiol. 10, 994–1007 (2008).18053004
113. Wood SJ Pseudomonas aeruginosa ExoT induces mitochondrial apoptosis in target host cells in a manner that depends on its GTPase-activating protein (GAP) domain activity J. Biol. Chem. 2015 290 29063 29073 26451042
Wood, S. J. et al. Pseudomonas aeruginosa ExoT induces mitochondrial apoptosis in target host cells in a manner that depends on its GTPase-activating protein (GAP) domain activity. J. Biol. Chem. 290, 29063–29073 (2015).26451042
114. Veshnyakova A On the interaction of Clostridium perfringens enterotoxin with claudins Toxins 2010 2 1336 1356 22069641
Veshnyakova, A. et al. On the interaction of Clostridium perfringens enterotoxin with claudins. Toxins 2, 1336–1356 (2010).22069641
115. Kominsky SL Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4 Am. J. Pathol. 2004 164 1627 1633 15111309
Kominsky, S. L. et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am. J. Pathol. 164, 1627–1633 (2004).15111309
116. Moghadam ZM Designing and analyzing the structure of DT-STXB fusion protein as an anti-tumor agent: an in silico approach Iran. J. Pathol. 2019 14 305 31754360
Moghadam, Z. M. et al. Designing and analyzing the structure of DT-STXB fusion protein as an anti-tumor agent: an in silico approach. Iran. J. Pathol. 14, 305 (2019).31754360
117. Wang H Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A Protein Expr. Purif. 2008 58 140 147 17950620
Wang, H. et al. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A. Protein Expr. Purif. 58, 140–147 (2008).17950620
118. Mohseni Z Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer Eur. J. Pharmacol. 2021 899 174057 33753109
Mohseni, Z. et al. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer. Eur. J. Pharmacol. 899, 174057 (2021).33753109
119. Patyar S Bacteria in cancer therapy: a novel experimental strategy J. Biomed. Sci. 2010 17 1 9 20055990
Patyar, S. et al. Bacteria in cancer therapy: a novel experimental strategy. J. Biomed. Sci. 17, 1–9 (2010).20055990
120. Barbé S Van Mellaert L Anné J The use of clostridial spores for cancer treatment J. Appl. Microbiol. 2006 101 571 578 16907807
Barbé, S., Van Mellaert, L. & Anné, J. The use of clostridial spores for cancer treatment. J. Appl. Microbiol. 101, 571–578 (2006).16907807
121. Yaghoubi A The use of Clostridium in cancer therapy: a promising way Rev. Med. Microbiol. 2022 33 121 127
Yaghoubi, A. et al. The use of Clostridium in cancer therapy: a promising way. Rev. Med. Microbiol. 33, 121–127 (2022).
122. Barbé S Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment FEMS Microbiol. 2005 246 67 73
Barbé, S. et al. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol. 246, 67–73 (2005).
123. Nelson BH IL-2, regulatory T cells, and tolerance J. Immunol. 2004 172 3983 3988 15034008
Nelson, B. H. IL-2, regulatory T cells, and tolerance. J. Immunol. 172, 3983–3988 (2004).15034008
124. Dinarello CA Novick D Kim S Kaplanski G Interleukin-18 and IL-18 binding protein Front. Immunol. 2013 4 289 24115947
Dinarello, C. A., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 4, 289 (2013).24115947
125. Saltzman DA Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent Cancer Biother. Radiopharm. 1996 11 145 153 10851531
Saltzman, D. A. et al. Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. Cancer Biother. Radiopharm. 11, 145–153 (1996).10851531
126. Loeffler M Le’Negrate G Krajewska M Reed JC IL-18-producing Salmonella inhibit tumor growth Cancer Gene Ther. 2008 15 787 794 18654612
Loeffler, M., Le’Negrate, G., Krajewska, M. & Reed, J. C. IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther. 15, 787–794 (2008).18654612
127. Ariyarathna H Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours Vet. Immunol. Immunopathol. 2020 230 110142 33129194
Ariyarathna, H. et al. Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours. Vet. Immunol. Immunopathol. 230, 110142 (2020).33129194
128. Zhang H Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer J. Exp. Clin. Cancer Res. 2021 40 1 22 33390177
Zhang, H. et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J. Exp. Clin. Cancer Res. 40, 1–22 (2021).33390177
129. Canale FP Metabolic modulation of tumours with engineered bacteria for immunotherapy Nature 2021 598 662 666 34616044
Canale, F. P. et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662–666 (2021).34616044
130. Gurbatri CR Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies Sci. Transl. Med. 2020 12 eaax0876 32051224
Gurbatri, C. R. et al. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci. Transl. Med. 12, eaax0876 (2020).32051224
131. Tian S Lin G Piao L Liu X Del-1 enhances therapeutic efficacy of bacterial cancer immunotherapy by blocking recruitment of tumor-infiltrating neutrophils Clin. Transl. Oncol. 2022 24 244 253 34236615
Tian, S., Lin, G., Piao, L. & Liu, X. Del-1 enhances therapeutic efficacy of bacterial cancer immunotherapy by blocking recruitment of tumor-infiltrating neutrophils. Clin. Transl. Oncol. 24, 244–253 (2022).34236615
132. Hu Q Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy Nano Lett. 2015 15 2732 2739 25806599
Hu, Q. et al. Engineering nanoparticle-coated bacteria as oral DNA vaccines for cancer immunotherapy. Nano Lett. 15, 2732–2739 (2015).25806599
133. Ni D Biomimetically engineered demi‐bacteria potentiate vaccination against cancer Adv. Sci. 2017 4 1700083
Ni, D. et al. Biomimetically engineered demi‐bacteria potentiate vaccination against cancer. Adv. Sci. 4, 1700083 (2017).
134. Wang W Mussel‐inspired polydopamine: the bridge for targeting drug delivery system and synergistic cancer treatment Macromol. Biosci. 2020 20 2000222
Wang, W. et al. Mussel‐inspired polydopamine: the bridge for targeting drug delivery system and synergistic cancer treatment. Macromol. Biosci. 20, 2000222 (2020).
135. Song Q A probiotic spore‐based oral autonomous nanoparticles generator for cancer therapy Adv. Mater. 2019 31 1903793
Song, Q. et al. A probiotic spore‐based oral autonomous nanoparticles generator for cancer therapy. Adv. Mater. 31, 1903793 (2019).
136. Zhang Y Design of outer membrane vesicles as cancer vaccines: a new toolkit for cancer therapy Cancers 2019 11 1314 31500086
Zhang, Y. et al. Design of outer membrane vesicles as cancer vaccines: a new toolkit for cancer therapy. Cancers 11, 1314 (2019).31500086
137. Gujrati V Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy ACS Nano. 2014 8 1525 1537 24410085
Gujrati, V. et al. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano. 8, 1525–1537 (2014).24410085
138. Zhang J Self-assembly catalase nanocomplex conveyed by bacterial vesicles for oxygenated photodynamic therapy and tumor immunotherapy Int. J. Nanomed. 2022 17 1971
Zhang, J. et al. Self-assembly catalase nanocomplex conveyed by bacterial vesicles for oxygenated photodynamic therapy and tumor immunotherapy. Int. J. Nanomed. 17, 1971 (2022).
139. Akhoundi M CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities Cell Oncol. 2021 44 495 523
Akhoundi, M. et al. CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cell Oncol. 44, 495–523 (2021).
140. Upadhaya S The clinical pipeline for cancer cell therapies Nat. Rev. Drug Discov. 2021 20 503 504 34088999
Upadhaya, S. et al. The clinical pipeline for cancer cell therapies. Nat. Rev. Drug Discov. 20, 503–504 (2021).34088999
141. Wang Z Wu Z Liu Y Han W New development in CAR-T cell therapy J. Hematol. Oncol. 2017 10 1 11 28049484
Wang, Z., Wu, Z., Liu, Y. & Han, W. New development in CAR-T cell therapy. J. Hematol. Oncol. 10, 1–11 (2017).28049484
142. Sengsayadeth S Savani BN Oluwole O Dholaria B Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice EJHaem 2022 3 6 10 35844299
Sengsayadeth, S., Savani, B. N., Oluwole, O. & Dholaria, B. Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem 3, 6–10 (2022).35844299
143. Qi C Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results Nat. Med. 2022 28 1189 1198 35534566
Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).35534566
144. Zhang C Zhuang Q Liu J Liu X Synthetic biology in chimeric antigen receptor T (CAR T) cell engineering ACS Synth. Biol. 2022 11 1 15 35005887
Zhang, C., Zhuang, Q., Liu, J. & Liu, X. Synthetic biology in chimeric antigen receptor T (CAR T) cell engineering. ACS Synth. Biol. 11, 1–15 (2022).35005887
145. Rafiq S Hackett CS Brentjens RJ Engineering strategies to overcome the current roadblocks in CAR T cell therapy Nat. Rev. Clin. Oncol. 2020 17 147 167 31848460
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).31848460
146. Yu S Yi M Qin S Wu K Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity Mol. Cancer 2019 18 1 13 30609930
Yu, S., Yi, M., Qin, S. & Wu, K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol. Cancer 18, 1–13 (2019).30609930
147. Andrea AE Chiron A Bessoles S Hacein-Bey-Abina S Engineering next-generation CAR-T cells for better toxicity management Int. J. Mol. Sci. 2020 21 8620 33207607
Andrea, A. E., Chiron, A., Bessoles, S. & Hacein-Bey-Abina, S. Engineering next-generation CAR-T cells for better toxicity management. Int. J. Mol. Sci. 21, 8620 (2020).33207607
148. Chang, P. S. et al. Manufacturing CD20/CD19-targeted iCasp9 regulatable CAR-TSCM cells using qCART, the Quantum pBac-based CAR-T system. Preprint at https://www.biorxiv.org/content/10.1101/2022.05.03.490475v2 (2022).
149. Prinzing B MyD88/CD40 signaling retains CAR T cells in a less differentiated state JCI Insight 2020 5 e136093 33148882
Prinzing, B. et al. MyD88/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight 5, e136093 (2020).33148882
150. Moghimi B Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma Nat. Commun. 2021 12 1 15 33397941
Moghimi, B. et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat. Commun. 12, 1–15 (2021).33397941
151. Hegde M Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape J. Clin. Investig. 2016 126 3036 3052 27427982
Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J. Clin. Investig. 126, 3036–3052 (2016).27427982
152. Han X Masked chimeric antigen receptor for tumor-specific activation Mol. Ther. 2017 25 274 284 28129121
Han, X. et al. Masked chimeric antigen receptor for tumor-specific activation. Mol. Ther. 25, 274–284 (2017).28129121
153. Yeku OO Brentjens RJ Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy Biochem. Soc. Trans. 2016 44 412 418 27068948
Yeku, O. O. & Brentjens, R. J. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem. Soc. Trans. 44, 412–418 (2016).27068948
154. Yeku OO Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment Sci. Rep. 2017 7 1 14 28127051
Yeku, O. O. et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci. Rep. 7, 1–14 (2017).28127051
155. Chmielewski M Abken H CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer Cancer Immunol. Immunother. 2012 61 1269 1277 22274776
Chmielewski, M. & Abken, H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol. Immunother. 61, 1269–1277 (2012).22274776
156. Lanitis E Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression J. Exp. Med. 2021 218 e20192203 33156338
Lanitis, E. et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J. Exp. Med. 218, e20192203 (2021).33156338
157. Hu B Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18 Cell Rep. 2017 20 3025 3033 28954221
Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025–3033 (2017).28954221
158. Vincent R Danino T CAR-T cells SEAK help from enzymes Nat. Chem. Biol. 2022 18 122 123 34969971
Vincent, R. & Danino, T. CAR-T cells SEAK help from enzymes. Nat. Chem. Biol. 18, 122–123 (2022).34969971
159. Durgin JS Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase Mol. Ther. 2022 30 1201 1214 34813961
Durgin, J. S. et al. Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase. Mol. Ther. 30, 1201–1214 (2022).34813961
160. Kuhn NF CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response Cancer Cell 2019 35 473 488.e476 30889381
Kuhn, N. F. et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473–488.e476 (2019).30889381
161. Jafarzadeh L Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells Mol. Immunol. 2021 139 1 9 34450537
Jafarzadeh, L. et al. Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells. Mol. Immunol. 139, 1–9 (2021).34450537
162. Li C Mei H Hu Y Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy Brief. Funct. Genomics 2020 19 175 182 31950135
Li, C., Mei, H. & Hu, Y. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. Brief. Funct. Genomics 19, 175–182 (2020).31950135
163. Lindahl JF Grace D The consequences of human actions on risks for infectious diseases: a review Infect. Ecol. Epidemiol. 2015 5 30048 26615822
Lindahl, J. F. & Grace, D. The consequences of human actions on risks for infectious diseases: a review. Infect. Ecol. Epidemiol. 5, 30048 (2015).26615822
164. Van Duin D Paterson DL Multidrug-resistant bacteria in the community: trends and lessons learned Infect. Dis. Clin. North Am. 2016 30 377 390 27208764
Van Duin, D. & Paterson, D. L. Multidrug-resistant bacteria in the community: trends and lessons learned. Infect. Dis. Clin. North Am. 30, 377–390 (2016).27208764
165. Chaoui L Mhand R Mellouki F Rhallabi N Contamination of the surfaces of a health care environment by multidrug-resistant (MDR) bacteria Int. J. Microbiol. 2019 2019 3236526 31871459
Chaoui, L., Mhand, R., Mellouki, F. & Rhallabi, N. Contamination of the surfaces of a health care environment by multidrug-resistant (MDR) bacteria. Int. J. Microbiol. 2019, 3236526 (2019).31871459
166. McDermott JE Computational prediction of type III and IV secreted effectors in gram-negative bacteria Infect. Immun. 2011 79 23 32 20974833
McDermott, J. E. et al. Computational prediction of type III and IV secreted effectors in gram-negative bacteria. Infect. Immun. 79, 23–32 (2011).20974833
167. Pinaud L Sansonetti PJ Phalipon A Host cell targeting by enteropathogenic bacteria T3SS effectors Trends Microbiol. 2018 26 266 283 29477730
Pinaud, L., Sansonetti, P. J. & Phalipon, A. Host cell targeting by enteropathogenic bacteria T3SS effectors. Trends Microbiol. 26, 266–283 (2018).29477730
168. Sperandio V Bacteria–host communication: the language of hormones Proc. Natl Acad. Sci. USA 2003 100 8951 8956 12847292
Sperandio, V. et al. Bacteria–host communication: the language of hormones. Proc. Natl Acad. Sci. USA 100, 8951–8956 (2003).12847292
169. Jana B Keppel K Salomon D Engineering a customizable antibacterial T6SS‐based platform in Vibrio natriegens EMBO Rep. 2021 22 e53681 34494702
Jana, B., Keppel, K. & Salomon, D. Engineering a customizable antibacterial T6SS‐based platform in Vibrio natriegens. EMBO Rep. 22, e53681 (2021).34494702
170. Ting S-Y Targeted depletion of bacteria from mixed populations by programmable adhesion with antagonistic competitor cells Cell Host Microbe 2020 28 313 321.e316 32470328
Ting, S.-Y. et al. Targeted depletion of bacteria from mixed populations by programmable adhesion with antagonistic competitor cells. Cell Host Microbe 28, 313–321.e316 (2020).32470328
171. Duan F March JC Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model Proc. Natl Acad. Sci. USA 2010 107 11260 11264 20534565
Duan, F. & March, J. C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl Acad. Sci. USA 107, 11260–11264 (2010).20534565
172. Hwang IY Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models Nat. Commun. 2017 8 1 11 28232747
Hwang, I. Y. et al. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat. Commun. 8, 1–11 (2017).28232747
173. Matteau D Rodrigue S An engineered Mycoplasma pneumoniae to fight Staphylococcus aureus Mol. Syst. Biol. 2021 17 e10574 34612591
Matteau, D. & Rodrigue, S. An engineered Mycoplasma pneumoniae to fight Staphylococcus aureus. Mol. Syst. Biol. 17, e10574 (2021).34612591
174. Jayakumar J Kumar V Biswas L Biswas R Therapeutic applications of lysostaphin against Staphylococcus aureus J. Appl. Microbiol. 2021 131 1072 1082 33382154
Jayakumar, J., Kumar, V., Biswas, L. & Biswas, R. Therapeutic applications of lysostaphin against Staphylococcus aureus. J. Appl. Microbiol. 131, 1072–1082 (2021).33382154
175. Jana B Keppel K Salomon D Engineering a customizable antibacterial T6SS-based platform in Vibrio natriegens EMBO Rep. 2021 22 e53681 34494702
Jana, B., Keppel, K. & Salomon, D. Engineering a customizable antibacterial T6SS-based platform in Vibrio natriegens. EMBO Rep. 22, e53681 (2021).34494702
176. Torres MD Synthetic biology and computer-based frameworks for antimicrobial peptide discovery ACS Nano. 2021 15 2143 2164 33538585
Torres, M. D. et al. Synthetic biology and computer-based frameworks for antimicrobial peptide discovery. ACS Nano. 15, 2143–2164 (2021).33538585
177. Fenton M McAuliffe O O’Mahony J Coffey A Recombinant bacteriophage lysins as antibacterials Bioeng. Bugs 2010 1 9 16 21327123
Fenton, M., McAuliffe, O., O’Mahony, J. & Coffey, A. Recombinant bacteriophage lysins as antibacterials. Bioeng. Bugs 1, 9–16 (2010).21327123
178. Ajuebor J Bacteriophage endolysins and their applications Sci. Prog. 2016 99 183 199 28742472
Ajuebor, J. et al. Bacteriophage endolysins and their applications. Sci. Prog. 99, 183–199 (2016).28742472
179. Meile S Engineering therapeutic phages for enhanced antibacterial efficacy Curr. Opin. Virol. 2022 52 182 191 34952266
Meile, S. et al. Engineering therapeutic phages for enhanced antibacterial efficacy. Curr. Opin. Virol. 52, 182–191 (2022).34952266
180. Masuda Y Construction of leaderless-bacteriocin-producing bacteriophage targeting E. coli and neighboring Gram-positive pathogens Microbiol. Spectr. 2021 9 e00141 00121
Masuda, Y. et al. Construction of leaderless-bacteriocin-producing bacteriophage targeting E. coli and neighboring Gram-positive pathogens. Microbiol. Spectr. 9, e00141–00121 (2021).
181. Hsu BB Way JC Silver PA Stable neutralization of a virulence factor in bacteria using temperate phage in the mammalian gut Msystems 2020 5 e00013 e00020 31992629
Hsu, B. B., Way, J. C. & Silver, P. A. Stable neutralization of a virulence factor in bacteria using temperate phage in the mammalian gut. Msystems 5, e00013–e00020 (2020).31992629
182. Cass J Barnard A Fairhead H Engineered bacteriophage as a delivery vehicle for antibacterial protein, SASP Pharmaceuticals 2021 14 1038 34681262
Cass, J., Barnard, A. & Fairhead, H. Engineered bacteriophage as a delivery vehicle for antibacterial protein, SASP. Pharmaceuticals 14, 1038 (2021).34681262
183. Chang TL-Y Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4 Proc. Natl Acad. Sci. USA 2003 100 11672 11677 12972635
Chang, T. L.-Y. et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc. Natl Acad. Sci. USA 100, 11672–11677 (2003).12972635
184. Rao S Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide Proc. Natl Acad. Sci. USA 2005 102 11993 11998 16040799
Rao, S. et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc. Natl Acad. Sci. USA 102, 11993–11998 (2005).16040799
185. Wei W Blocking HIV-1 infection by chromosomal integrative expression of human CD4 on the surface of Lactobacillus acidophilus ATCC 4356 J. Virol. 2019 93 e01830 01818 30728264
Wei, W. et al. Blocking HIV-1 infection by chromosomal integrative expression of human CD4 on the surface of Lactobacillus acidophilus ATCC 4356. J. Virol. 93, e01830–01818 (2019).30728264
186. Martins DP Computational models for trapping ebola virus using engineered bacteria IEEE/ACM Trans. Comput Biol. Bioinform. 2018 15 2017 2027 29994771
Martins, D. P. et al. Computational models for trapping ebola virus using engineered bacteria. IEEE/ACM Trans. Comput Biol. Bioinform. 15, 2017–2027 (2018).29994771
187. Wang H Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 Lancet 2022 399 1513 1536 35279232
Wang, H. et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet 399, 1513–1536 (2022).35279232
188. Ciotti M The COVID-19 pandemic Crit. Rev. Clin. Lab Sci. 2020 57 365 388 32645276
Ciotti, M. et al. The COVID-19 pandemic. Crit. Rev. Clin. Lab Sci. 57, 365–388 (2020).32645276
189. Chen WH Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate Biochim Biophys. Acta Gen. Subj. 2021 1865 129893 33731300
Chen, W. H. et al. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochim Biophys. Acta Gen. Subj. 1865, 129893 (2021).33731300
190. Pino M A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates Sci. Immunol. 2021 6 eabh3634 34266981
Pino, M. et al. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci. Immunol. 6, eabh3634 (2021).34266981
191. Turner JS SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses Nature 2021 596 109 113 34182569
Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 596, 109–113 (2021).34182569
192. Thi Nhu Thao T Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform Nature 2020 582 561 565 32365353
Thi Nhu Thao, T. et al. Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. Nature 582, 561–565 (2020).32365353
193. Xue KS Moncla LH Bedford T Bloom JD Within-host evolution of human influenza virus Trends Microbiol. 2018 26 781 793 29534854
Xue, K. S., Moncla, L. H., Bedford, T. & Bloom, J. D. Within-host evolution of human influenza virus. Trends Microbiol. 26, 781–793 (2018).29534854
194. Koonin EV Dolja VV Krupovic M The logic of virus evolution Cell Host Microbe 2022 30 917 929 35834963
Koonin, E. V., Dolja, V. V. & Krupovic, M. The logic of virus evolution. Cell Host Microbe 30, 917–929 (2022).35834963
195. Shafquat A Joice R Simmons SL Huttenhower C Functional and phylogenetic assembly of microbial communities in the human microbiome Trends Microbiol. 2014 22 261 266 24618403
Shafquat, A., Joice, R., Simmons, S. L. & Huttenhower, C. Functional and phylogenetic assembly of microbial communities in the human microbiome. Trends Microbiol. 22, 261–266 (2014).24618403
196. Berrilli F Di Cave D Cavallero S D’Amelio S Interactions between parasites and microbial communities in the human gut Front. Cell. Infect. Microbiol. 2012 2 141 23162802
Berrilli, F., Di Cave, D., Cavallero, S. & D’Amelio, S. Interactions between parasites and microbial communities in the human gut. Front. Cell. Infect. Microbiol. 2, 141 (2012).23162802
197. Robinson CJ Bohannan BJ Young VB From structure to function: the ecology of host-associated microbial communities Microbiol. Mol. Biol. Rev. 2010 74 453 476 20805407
Robinson, C. J., Bohannan, B. J. & Young, V. B. From structure to function: the ecology of host-associated microbial communities. Microbiol. Mol. Biol. Rev. 74, 453–476 (2010).20805407
198. Rosenfeld CS Microbiome disturbances and autism spectrum disorders Drug Metab. Dispos. 2015 43 1557 1571 25852213
Rosenfeld, C. S. Microbiome disturbances and autism spectrum disorders. Drug Metab. Dispos. 43, 1557–1571 (2015).25852213
199. Genua F The role of gut barrier dysfunction and microbiome dysbiosis in colorectal cancer development Front. Oncol. 2021 11 626349 33937029
Genua, F. et al. The role of gut barrier dysfunction and microbiome dysbiosis in colorectal cancer development. Front. Oncol. 11, 626349 (2021).33937029
200. Sharma S Tripathi P Gut microbiome and type 2 diabetes: where we are and where to go? J. Nutr. Biochem. 2019 63 101 108 30366260
Sharma, S. & Tripathi, P. Gut microbiome and type 2 diabetes: where we are and where to go? J. Nutr. Biochem. 63, 101–108 (2019).30366260
201. Sikalidis AK Maykish A The gut microbiome and type 2 diabetes mellitus: discussing a complex relationship Biomedicines 2020 8 8 31936158
Sikalidis, A. K. & Maykish, A. The gut microbiome and type 2 diabetes mellitus: discussing a complex relationship. Biomedicines 8, 8 (2020).31936158
202. Bien J Palagani V Bozko P The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther. Adv. Gastroenterol. 2013 6 53 68
Bien, J., Palagani, V. & Bozko, P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther. Adv. Gastroenterol. 6, 53–68 (2013).
203. Antharam VC Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea J. Clin. Microbiol. 2013 51 2884 2892 23804381
Antharam, V. C. et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 51, 2884–2892 (2013).23804381
204. Engevik MA Human Clostridium difficile infection: altered mucus production and composition Am. J. Physiol. Gastrointest. Liver Physiol. 2015 308 G510 G524 25552581
Engevik, M. A. et al. Human Clostridium difficile infection: altered mucus production and composition. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G510–G524 (2015).25552581
205. Loh G Blaut M Role of commensal gut bacteria in inflammatory bowel diseases Gut microbes 2012 3 544 555 23060017
Loh, G. & Blaut, M. Role of commensal gut bacteria in inflammatory bowel diseases. Gut microbes 3, 544–555 (2012).23060017
206. Lee Y Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis Nat. Mater. 2020 19 118 126 31427744
Lee, Y. et al. Hyaluronic acid–bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat. Mater. 19, 118–126 (2020).31427744
207. Whelan RA A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation Mol. Ther. 2014 22 1730 1740 24985163
Whelan, R. A. et al. A transgenic probiotic secreting a parasite immunomodulator for site-directed treatment of gut inflammation. Mol. Ther. 22, 1730–1740 (2014).24985163
208. Carroll IM Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis Am. J. Physiol. Gastrointest. Liver Physiol. 2007 293 G729 G738 17640978
Carroll, I. M. et al. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide dismutase using the interleukin 10-deficient mouse model of colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G729–G738 (2007).17640978
209. Yan X Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis Cell. Mol. Immunol. 2021 18 2344 2357 34480146
Yan, X. et al. Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis. Cell. Mol. Immunol. 18, 2344–2357 (2021).34480146
210. Eisen A Calne D Amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease: phylogenetic disorders of the human neocortex sharing many characteristics Can. J. Neurol. Sci. 1992 19 117 123 1571856
Eisen, A. & Calne, D. Amyotrophic lateral sclerosis, Parkinson’s disease and Alzheimer’s disease: phylogenetic disorders of the human neocortex sharing many characteristics. Can. J. Neurol. Sci. 19, 117–123 (1992).1571856
211. Sarkar SR Banerjee S Gut microbiota in neurodegenerative disorders J. Neuroimmunol. 2019 328 98 104 30658292
Sarkar, S. R. & Banerjee, S. Gut microbiota in neurodegenerative disorders. J. Neuroimmunol. 328, 98–104 (2019).30658292
212. Chidambaram SB Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: tales of a vicious cycle Pharmacol. Ther. 2021 231 107988 34536490
Chidambaram, S. B. et al. Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: tales of a vicious cycle. Pharmacol. Ther. 231, 107988 (2021).34536490
213. Wu S-C Cao Z-S Chang K-M Juang J-L Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila Nat. Commun. 2017 8 1 9 28232747
Wu, S.-C., Cao, Z.-S., Chang, K.-M. & Juang, J.-L. Intestinal microbial dysbiosis aggravates the progression of Alzheimer’s disease in Drosophila. Nat. Commun. 8, 1–9 (2017).28232747
214. Duan FF Liu JH March JC Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes Diabetes 2015 64 1794 1803 25626737
Duan, F. F., Liu, J. H. & March, J. C. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64, 1794–1803 (2015).25626737
215. Wang L Engineered bacteria of MG1363-pMG36e-GLP-1 attenuated obesity-induced by high fat diet in mice Front. Cell. Infect. Microbiol. 2021 11 595575 33732656
Wang, L. et al. Engineered bacteria of MG1363-pMG36e-GLP-1 attenuated obesity-induced by high fat diet in mice. Front. Cell. Infect. Microbiol. 11, 595575 (2021).33732656
216. Fang X Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease AMB Express 2020 10 80 32333225
Fang, X. et al. Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease. AMB Express 10, 80 (2020).32333225
217. May-Zhang LS Administration of N-acyl-phosphatidylethanolamine expressing bacteria to low density lipoprotein receptor(-/-) mice improves indices of cardiometabolic disease Sci. Rep. 2019 9 420 30674978
May-Zhang, L. S. et al. Administration of N-acyl-phosphatidylethanolamine expressing bacteria to low density lipoprotein receptor(-/-) mice improves indices of cardiometabolic disease. Sci. Rep. 9, 420 (2019).30674978
218. Feyisetan O Tracey C Hellawell GO Probiotics, dendritic cells and bladder cancer BJU Int. 2012 109 1594 1597 22176770
Feyisetan, O., Tracey, C. & Hellawell, G. O. Probiotics, dendritic cells and bladder cancer. BJU Int. 109, 1594–1597 (2012).22176770
219. Cecarini V Neuroprotective effects of p62 (SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study Aging 2020 12 15995 32855357
Cecarini, V. et al. Neuroprotective effects of p62 (SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study. Aging 12, 15995 (2020).32855357
220. Den H Dong X Chen M Zou Z Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment—a meta-analysis of randomized controlled trials Aging 2020 12 4010 32062613
Den, H., Dong, X., Chen, M. & Zou, Z. Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment—a meta-analysis of randomized controlled trials. Aging 12, 4010 (2020).32062613
221. Hwang IY Chang MW Engineering commensal bacteria to rewire host-microbiome interactions Curr. Opin. Biotechnol. 2020 62 116 122 31654857
Hwang, I. Y. & Chang, M. W. Engineering commensal bacteria to rewire host-microbiome interactions. Curr. Opin. Biotechnol. 62, 116–122 (2020).31654857
222. Sadaka C Damborg P Watts JL High-throughput screen identifying the thiosemicarbazone NSC319726 compound as a potent antimicrobial lead against resistant strains of Escherichia coli Biomolecules 2018 8 166 173 30544635
Sadaka, C., Damborg, P. & Watts, J. L. High-throughput screen identifying the thiosemicarbazone NSC319726 compound as a potent antimicrobial lead against resistant strains of Escherichia coli. Biomolecules 8, 166–173 (2018).30544635
223. Male AL Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interaction Sci. Rep. 2017 7 3104 3112 28596569
Male, A. L. et al. Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interaction. Sci. Rep. 7, 3104–3112 (2017).28596569
224. Yang X A lanthipeptide library used to identify a protein-protein interaction inhibitor Nat. Chem. Biol. 2018 14 375 380 29507389
Yang, X. et al. A lanthipeptide library used to identify a protein-protein interaction inhibitor. Nat. Chem. Biol. 14, 375–380 (2018).29507389
225. Li CQ Recent advances in the synthetic biology of natural drugs Front. Bioeng. Biotechnol. 2021 9 691152 34395399
Li, C. Q. et al. Recent advances in the synthetic biology of natural drugs. Front. Bioeng. Biotechnol. 9, 691152 (2021).34395399
226. Baghban R Yeast expression systems: overview and recent advances Mol. Biotechnol. 2019 61 365 384 30805909
Baghban, R. et al. Yeast expression systems: overview and recent advances. Mol. Biotechnol. 61, 365–384 (2019).30805909
227. Perkins E Novel inhibitors of Poly(ADP-ribose) polymerase PARP1 and PARP2 identified using a cell-based screen in yeast Cancer Res. 2001 61 4175 4183 11358842
Perkins, E. et al. Novel inhibitors of Poly(ADP-ribose) polymerase PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res. 61, 4175–4183 (2001).11358842
228. Birrell GW A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity Proc. Natl Acad. Sci. USA 2001 98 12608 12613 11606770
Birrell, G. W. et al. A genome-wide screen in Saccharomyces cerevisiae for genes affecting UV radiation sensitivity. Proc. Natl Acad. Sci. USA 98, 12608–12613 (2001).11606770
229. Hultquist JF CRISPR-Cas9 genome engineering of primary CD4(+) T cells for the interrogation of HIV-host factor interactions Nat. Protoc. 2019 14 1 27 30559373
Hultquist, J. F. et al. CRISPR-Cas9 genome engineering of primary CD4(+) T cells for the interrogation of HIV-host factor interactions. Nat. Protoc. 14, 1–27 (2019).30559373
230. Fussenegger M Streptogramin-based gene regulation systems for mammalian cells Nat. Biotechnol. 2000 18 1203 1208 11062442
Fussenegger, M. et al. Streptogramin-based gene regulation systems for mammalian cells. Nat. Biotechnol. 18, 1203–1208 (2000).11062442
231. Aubel D Design of a novel mammalian screening system for the detection of bioavailable, non-cytotoxic streptogramin antibiotics J. Antibiot. 2001 54 44 55
Aubel, D. et al. Design of a novel mammalian screening system for the detection of bioavailable, non-cytotoxic streptogramin antibiotics. J. Antibiot. 54, 44–55 (2001).
232. Baulard AR Activation of the pro-drug ethionamide is regulated in mycobacteria J. Biol. Chem. 2000 275 28326 28331 10869356
Baulard, A. R. et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 275, 28326–28331 (2000).10869356
233. Weber W A synthetic mammalian gene circuit reveals antituberculosis compounds Proc. Natl Acad. Sci. USA 2008 105 9994 9998 18621677
Weber, W. et al. A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl Acad. Sci. USA 105, 9994–9998 (2008).18621677
234. Tu Y The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine Nat. Med. 2011 17 1217 1220 21989013
Tu, Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat. Med. 17, 1217–1220 (2011).21989013
235. Li D Zhang J Zhao X Mechanisms and molecular targets of artemisinin in cancer treatment Cancer Invest. 2021 39 675 684 34241563
Li, D., Zhang, J. & Zhao, X. Mechanisms and molecular targets of artemisinin in cancer treatment. Cancer Invest. 39, 675–684 (2021).34241563
236. Cheong DHJ Tan DWS Wong FWS Tran T Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases Pharmacol. Res. 2020 158 104901 32405226
Cheong, D. H. J., Tan, D. W. S., Wong, F. W. S. & Tran, T. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases. Pharmacol. Res. 158, 104901 (2020).32405226
237. Efferth T Beyond malaria: the inhibition of viruses by artemisinin-type compounds Biotechnol. Adv. 2018 36 1730 1737 29305894
Efferth, T. Beyond malaria: the inhibition of viruses by artemisinin-type compounds. Biotechnol. Adv. 36, 1730–1737 (2018).29305894
238. Uckun FM Saund S Windlass H Trieu V Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug Front. Pharmacol. 2021 12 649532 33815126
Uckun, F. M., Saund, S., Windlass, H. & Trieu, V. Repurposing anti-malaria phytomedicine artemisinin as a COVID-19 drug. Front. Pharmacol. 12, 649532 (2021).33815126
239. Martin VJ Engineering a mevalonate pathway in E. coli for production of terpenoids Nat. Biotechnol. 2003 21 796 802 12778056
Martin, V. J. et al. Engineering a mevalonate pathway in E. coli for production of terpenoids. Nat. Biotechnol. 21, 796–802 (2003).12778056
240. Ro DK Production of the antimalarial drug precursor artemisinic acid in engineered yeast Nature 2006 440 940 943 16612385
Ro, D. K. et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440, 940–943 (2006).16612385
241. Paddon CJ High-level semi-synthetic production of the potent antimalarial artemisinin Nature 2013 496 528 532 23575629
Paddon, C. J. et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496, 528–532 (2013).23575629
242. Farhi M Generation of the potent anti-malarial drug artemisinin in tobacco Nat. Biotechnol. 2011 29 1072 1074 22158354
Farhi, M. et al. Generation of the potent anti-malarial drug artemisinin in tobacco. Nat. Biotechnol. 29, 1072–1074 (2011).22158354
243. Khairul Ikram NKB Stable production of the antimalarial drug artemisinin in the moss Physcomitrella patens Front. Bioeng. Biotechnol. 2017 5 47 28861412
Khairul Ikram, N. K. B. et al. Stable production of the antimalarial drug artemisinin in the moss Physcomitrella patens. Front. Bioeng. Biotechnol. 5, 47 (2017).28861412
244. Wani MC Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia J. Am. Chem. Soc. 1971 93 2325 2327 5553076
Wani, M. C. et al. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93, 2325–2327 (1971).5553076
245. Abu Samaan TM Paclitaxel’s mechanistic and clinical effects on breast cancer Biomolecules 2019 9 789 31783552
Abu Samaan, T. M. et al. Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules 9, 789 (2019).31783552
246. Bookman MA Optimal primary therapy of ovarian cancer Ann. Oncol. 2016 27 Suppl 1 i58 i62 27141074
Bookman, M. A. Optimal primary therapy of ovarian cancer. Ann. Oncol. 27(Suppl 1), i58–i62 (2016).27141074
247. Lemstrova R Melichar B Mohelnikova-Duchonova B Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer Cancer Chemother. Pharmacol. 2016 78 1101 1111 27250969
Lemstrova, R., Melichar, B. & Mohelnikova-Duchonova, B. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. Cancer Chemother. Pharmacol. 78, 1101–1111 (2016).27250969
248. Joshi M Liu X Belani CP Taxanes, past, present, and future impact on non-small cell lung cancer Anticancer Drugs 2014 25 571 583 24463482
Joshi, M., Liu, X. & Belani, C. P. Taxanes, past, present, and future impact on non-small cell lung cancer. Anticancer Drugs 25, 571–583 (2014).24463482
249. Zhu ML Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Res. 2010 70 7992 8002 20807808
Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992–8002 (2010).20807808
250. Huang Q Roessner CA Croteau R Scott AI Engineering Escherichia coli for the synthesis of taxadiene, a key intermediate in the biosynthesis of taxol Bioorg. Med. Chem. 2001 9 2237 2242 11553461
Huang, Q., Roessner, C. A., Croteau, R. & Scott, A. I. Engineering Escherichia coli for the synthesis of taxadiene, a key intermediate in the biosynthesis of taxol. Bioorg. Med. Chem. 9, 2237–2242 (2001).11553461
251. Ajikumar PK Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli Science 2010 330 70 74 20929806
Ajikumar, P. K. et al. Isoprenoid pathway optimization for Taxol precursor overproduction in Escherichia coli. Science 330, 70–74 (2010).20929806
252. Nowrouzi B Enhanced production of taxadiene in Saccharomyces cerevisiae Microb. Cell Fact. 2020 19 200 33138820
Nowrouzi, B. et al. Enhanced production of taxadiene in Saccharomyces cerevisiae. Microb. Cell Fact. 19, 200 (2020).33138820
253. Walls LE Martinez JL Rios-Solis L Enhancing Saccharomyces cerevisiae taxane biosynthesis and overcoming nutritional stress-induced pseudohyphal growth Microorganisms 2022 10 163 35056611
Walls, L. E., Martinez, J. L. & Rios-Solis, L. Enhancing Saccharomyces cerevisiae taxane biosynthesis and overcoming nutritional stress-induced pseudohyphal growth. Microorganisms 10, 163 (2022).35056611
254. Zhou K Qiao K Edgar S Stephanopoulos G Distributing a metabolic pathway among a microbial consortium enhances production of natural products Nat. Biotechnol. 2015 33 377 383 25558867
Zhou, K., Qiao, K., Edgar, S. & Stephanopoulos, G. Distributing a metabolic pathway among a microbial consortium enhances production of natural products. Nat. Biotechnol. 33, 377–383 (2015).25558867
255. Li J Chloroplastic metabolic engineering coupled with isoprenoid pool enhancement for committed taxanes biosynthesis in Nicotiana benthamiana Nat. Commun. 2019 10 4850 31649252
Li, J. et al. Chloroplastic metabolic engineering coupled with isoprenoid pool enhancement for committed taxanes biosynthesis in Nicotiana benthamiana. Nat. Commun. 10, 4850 (2019).31649252
256. Xu J Ethnopharmacology, phytochemistry, and pharmacology of Chinese Salvia species: a review J. Ethnopharmacol. 2018 225 18 30 29935346
Xu, J. et al. Ethnopharmacology, phytochemistry, and pharmacology of Chinese Salvia species: a review. J. Ethnopharmacol. 225, 18–30 (2018).29935346
257. Zhou YJ Modular pathway engineering of diterpenoid synthases and the mevalonic acid pathway for miltiradiene production J. Am. Chem. Soc. 2012 134 3234 3241 22280121
Zhou, Y. J. et al. Modular pathway engineering of diterpenoid synthases and the mevalonic acid pathway for miltiradiene production. J. Am. Chem. Soc. 134, 3234–3241 (2012).22280121
258. Hu T Engineering chimeric diterpene synthases and isoprenoid biosynthetic pathways enables high-level production of miltiradiene in yeast Metab. Eng. 2020 60 87 96 32268192
Hu, T. et al. Engineering chimeric diterpene synthases and isoprenoid biosynthetic pathways enables high-level production of miltiradiene in yeast. Metab. Eng. 60, 87–96 (2020).32268192
259. Kai G Metabolic engineering tanshinone biosynthetic pathway in Salvia miltiorrhiza hairy root cultures Metab. Eng. 2011 13 319 327 21335099
Kai, G. et al. Metabolic engineering tanshinone biosynthetic pathway in Salvia miltiorrhiza hairy root cultures. Metab. Eng. 13, 319–327 (2011).21335099
260. Galanie S Complete biosynthesis of opioids in yeast Science 2015 349 1095 1100 26272907
Galanie, S. et al. Complete biosynthesis of opioids in yeast. Science 349, 1095–1100 (2015).26272907
261. Luo X Complete biosynthesis of cannabinoids and their unnatural analogues in yeast Nature 2019 567 123 126 30814733
Luo, X. et al. Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. Nature 567, 123–126 (2019).30814733
262. Leader B Baca QJ Golan DE Protein therapeutics a summary and pharmacological classification Nat. Rev. Drug Discov. 2008 7 21 39 18097458
Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics a summary and pharmacological classification. Nat. Rev. Drug Discov. 7, 21–39 (2008).18097458
263. Chance RE Frank BH Research, development, production, and safety of biosynthetic human insulin Diabetes Care 1993 16 133 142 8299470
Chance, R. E. & Frank, B. H. Research, development, production, and safety of biosynthetic human insulin. Diabetes Care 16, 133–142 (1993).8299470
264. Govender K A novel and more efficient biosynthesis approach for human insulin production in Escherichia coli (E. coli) AMB Express 2020 10 43 32152803
Govender, K. et al. A novel and more efficient biosynthesis approach for human insulin production in Escherichia coli (E. coli). AMB Express 10, 43 (2020).32152803
265. Kjeldsen T Yeast secretory expression of insulin precursors Appl. Microbiol. Biotechnol. 2000 54 277 286 11030562
Kjeldsen, T. Yeast secretory expression of insulin precursors. Appl. Microbiol. Biotechnol. 54, 277–286 (2000).11030562
266. Bucchini D Pancreatic expression of human insulin gene in transgenic mice Proc. Natl Acad. Sci. USA 1986 83 2511 2515 3517871
Bucchini, D. et al. Pancreatic expression of human insulin gene in transgenic mice. Proc. Natl Acad. Sci. USA 83, 2511–2515 (1986).3517871
267. Nykiforuk CL Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds Plant Biotechnol. J. 2006 4 77 85 17177787
Nykiforuk, C. L. et al. Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds. Plant Biotechnol. J. 4, 77–85 (2006).17177787
268. Abookazemi K Jalali J Mohebodini M Vaseghi A Transfer of human proinsulin gene into Cucumber (Cucumis sativus L.) via agrobacterium method Genetika 2017 49 717 728
Abookazemi, K., Jalali, J., Mohebodini, M. & Vaseghi, A. Transfer of human proinsulin gene into Cucumber (Cucumis sativus L.) via agrobacterium method. Genetika 49, 717–728 (2017).
269. Zhang J Synthetic sRNA-based engineering of Escherichia coli for enhanced production of full-length immunoglobulin G J. Biotechnol. 2020 15 e1900363
Zhang, J. et al. Synthetic sRNA-based engineering of Escherichia coli for enhanced production of full-length immunoglobulin G. J. Biotechnol. 15, e1900363 (2020).
270. Shirley M Dhillon S Bivalent rLP2086 vaccine (Trumenba(R)): a review in active immunization against invasive meningococcal group B disease in individuals aged 10–25 years BioDrugs 2015 29 353 361 26394633
Shirley, M. & Dhillon, S. Bivalent rLP2086 vaccine (Trumenba(R)): a review in active immunization against invasive meningococcal group B disease in individuals aged 10–25 years. BioDrugs 29, 353–361 (2015).26394633
271. Claudia Figueiredo M Vaccination against human papillomavirus Einstein 2013 11 547 549 24488402
Claudia Figueiredo, M. Vaccination against human papillomavirus. Einstein 11, 547–549 (2013).24488402
272. Dai L A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS Cell 2020 182 722 733.e711 32645327
Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722–733.e711 (2020).32645327
273. Meng FY Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials Signal Transduct. Target Ther. 2021 6 271 34267185
Meng, F. Y. et al. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. Signal Transduct. Target Ther. 6, 271 (2021).34267185
274. Zhao C Conformational remodeling enhances activity of lanthipeptide zinc-metallopeptidases Nat. Chem. Biol. 2022 18 724 732 35513512
Zhao, C. et al. Conformational remodeling enhances activity of lanthipeptide zinc-metallopeptidases. Nat. Chem. Biol. 18, 724–732 (2022).35513512
275. Pane K Rational design of a carrier protein for the production of recombinant toxic peptides in Escherichia coli PLoS ONE 2016 11 e0146552 26808536
Pane, K. et al. Rational design of a carrier protein for the production of recombinant toxic peptides in Escherichia coli. PLoS ONE 11, e0146552 (2016).26808536
276. Ishida H Overexpression of antimicrobial, anticancer, and transmembrane peptides in Escherichia coli through a calmodulin-peptide fusion system J. Am. Chem. Soc. 2016 138 11318 11326 27502305
Ishida, H. et al. Overexpression of antimicrobial, anticancer, and transmembrane peptides in Escherichia coli through a calmodulin-peptide fusion system. J. Am. Chem. Soc. 138, 11318–11326 (2016).27502305
277. Zhang X Identification of heptapeptides targeting a lethal bacterial strain in septic mice through an integrative approach Signal Transduct. Target Ther. 2022 7 245 35871689
Zhang, X. et al. Identification of heptapeptides targeting a lethal bacterial strain in septic mice through an integrative approach. Signal Transduct. Target Ther. 7, 245 (2022).35871689
278. Chen X High-level heterologous production and functional secretion by recombinant Pichia pastoris of the shortest proline-rich antibacterial honeybee peptide Apidaecin Sci. Rep. 2017 7 14543 29109421
Chen, X. et al. High-level heterologous production and functional secretion by recombinant Pichia pastoris of the shortest proline-rich antibacterial honeybee peptide Apidaecin. Sci. Rep. 7, 14543 (2017).29109421
279. Guo C Secretion and activity of antimicrobial peptide cecropin D expressed in Pichia pastoris Exp. Ther. Med. 2012 4 1063 1068 23226775
Guo, C. et al. Secretion and activity of antimicrobial peptide cecropin D expressed in Pichia pastoris. Exp. Ther. Med. 4, 1063–1068 (2012).23226775
280. Wang A High level expression and purification of bioactive human alpha-defensin 5 mature peptide in Pichia pastoris Appl. Microbiol. Biotechnol. 2009 84 877 884 19448999
Wang, A. et al. High level expression and purification of bioactive human alpha-defensin 5 mature peptide in Pichia pastoris. Appl. Microbiol. Biotechnol. 84, 877–884 (2009).19448999
281. Huang S The nonribosomal peptide valinomycin: from discovery to bioactivity and biosynthesis Microorganisms 2021 9 780 33917912
Huang, S. et al. The nonribosomal peptide valinomycin: from discovery to bioactivity and biosynthesis. Microorganisms 9, 780 (2021).33917912
282. Zhuang L Total in vitro biosynthesis of the nonribosomal macrolactone peptide valinomycin Metab. Eng. 2020 60 37 44 32224263
Zhuang, L. et al. Total in vitro biosynthesis of the nonribosomal macrolactone peptide valinomycin. Metab. Eng. 60, 37–44 (2020).32224263
283. Liu R A cell-free platform based on nisin biosynthesis for discovering novel lanthipeptides and guiding their overproduction in vivo Adv. Sci. 2020 7 2001616
Liu, R. et al. A cell-free platform based on nisin biosynthesis for discovering novel lanthipeptides and guiding their overproduction in vivo. Adv. Sci. 7, 2001616 (2020).
284. Si Y Cell-free biosynthesis to evaluate lasso peptide formation and enzyme-substrate tolerance J. Am. Chem. Soc. 2021 143 5917 5927 33823110
Si, Y. et al. Cell-free biosynthesis to evaluate lasso peptide formation and enzyme-substrate tolerance. J. Am. Chem. Soc. 143, 5917–5927 (2021).33823110
285. Callaway E The race for coronavirus vaccines: a graphical guide Nature 2020 580 576 577 32346146
Callaway, E. The race for coronavirus vaccines: a graphical guide. Nature 580, 576–577 (2020).32346146
286. Tebas P Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial EClinicalMedicine 2021 31 100689 33392485
Tebas, P. et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, Phase 1 clinical trial. EClinicalMedicine 31, 100689 (2021).33392485
287. Bandaru R Clinical progress of therapeutics and vaccines: rising hope against COVID-19 treatment Process Biochem. 2022 118 154 170 35437418
Bandaru, R. et al. Clinical progress of therapeutics and vaccines: rising hope against COVID-19 treatment. Process Biochem. 118, 154–170 (2022).35437418
288. Takiishi T Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T Cells Diabetes 2017 66 448 459 28108611
Takiishi, T. et al. Reversal of diabetes in NOD mice by clinical-grade proinsulin and IL-10-secreting lactococcus lactis in combination with low-dose anti-CD3 depends on the induction of Foxp3-positive T Cells. Diabetes 66, 448–459 (2017).28108611
289. Zheng JH Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin Sci. Transl. Med. 2017 9 1 10
Zheng, J. H. et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci. Transl. Med. 9, 1–10 (2017).
290. Tew D Synthetic biology and healthcare Emerg. Top. Life Sci. 2019 3 659 667 33523174
Tew, D. Synthetic biology and healthcare. Emerg. Top. Life Sci. 3, 659–667 (2019).33523174
291. Sun W Jiang Z Jiang W Yang R Universal chimeric antigen receptor T cell therapy—the future of cell therapy: a review providing clinical evidence Cancer Treat. Res. Commun. 2022 33 100638 36184307
Sun, W., Jiang, Z., Jiang, W. & Yang, R. Universal chimeric antigen receptor T cell therapy—the future of cell therapy: a review providing clinical evidence. Cancer Treat. Res. Commun. 33, 100638 (2022).36184307
292. Foss DV Hochstrasser ML Wilson RC Clinical applications of CRISPR-based genome editing and diagnostics Transfusion 2019 59 1389 1399 30600536
Foss, D. V., Hochstrasser, M. L. & Wilson, R. C. Clinical applications of CRISPR-based genome editing and diagnostics. Transfusion 59, 1389–1399 (2019).30600536
293. McNerney MP Watstein DM Styczynski MP Precision metabolic engineering: the design of responsive, selective, and controllable metabolic systems Metab. Eng. 2015 31 123 131 26189665
McNerney, M. P., Watstein, D. M. & Styczynski, M. P. Precision metabolic engineering: the design of responsive, selective, and controllable metabolic systems. Metab. Eng. 31, 123–131 (2015).26189665
294. Santos-Moreno J Schaerli Y Using synthetic biology to engineer spatial patterns Adv. Biosyst. 2019 3 e1800280 32627430
Santos-Moreno, J. & Schaerli, Y. Using synthetic biology to engineer spatial patterns. Adv. Biosyst. 3, e1800280 (2019).32627430
295. Ohta, K., Sakoda, Y. & Tamada, K. Novel technologies for improving the safety and efficacy of CAR-T cell therapy. Int. J. Hematol. (2022).
296. Gujrati V Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging Nat. Commun. 2019 10 1114 30846699
Gujrati, V. et al. Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging. Nat. Commun. 10, 1114 (2019).30846699
297. Low KB Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo Nat. Biotechnol. 1999 17 37 41 9920266
Low, K. B. et al. Lipid A mutant Salmonella with suppressed virulence and TNFα induction retain tumor-targeting in vivo. Nat. Biotechnol. 17, 37–41 (1999).9920266
298. Afkhami-Poostchi A Mashreghi M Iranshahi M Matin MM Use of a genetically engineered E. coli overexpressing β-glucuronidase accompanied by glycyrrhizic acid, a natural and anti-inflammatory agent, for directed treatment of colon carcinoma in a mouse model Int. J. Pharm. 2020 579 119159 32081798
Afkhami-Poostchi, A., Mashreghi, M., Iranshahi, M. & Matin, M. M. Use of a genetically engineered E. coli overexpressing β-glucuronidase accompanied by glycyrrhizic acid, a natural and anti-inflammatory agent, for directed treatment of colon carcinoma in a mouse model. Int. J. Pharm. 579, 119159 (2020).32081798
299. Broadway KM Suh S Behkam B Scharf BE Optimizing the restored chemotactic behavior of anticancer agent Salmonella enterica serovar Typhimurium VNP20009 J. Biotechnol. 2017 251 76 83 28433721
Broadway, K. M., Suh, S., Behkam, B. & Scharf, B. E. Optimizing the restored chemotactic behavior of anticancer agent Salmonella enterica serovar Typhimurium VNP20009. J. Biotechnol. 251, 76–83 (2017).28433721
300. Janku F Abstract CT110: intratumoral injection of SYNB1891, a synthetic biotic designed to activate the innate immune system, demonstrates target engagement in humans including intratumoral STING activation Cancer Res. 2021 81 CT110
Janku, F. et al. Abstract CT110: intratumoral injection of SYNB1891, a synthetic biotic designed to activate the innate immune system, demonstrates target engagement in humans including intratumoral STING activation. Cancer Res. 81, CT110 (2021).
301. Schöder H Considerations on integrating prostate-specific membrane antigen positron emission tomography imaging into clinical prostate cancer trials by National Clinical Trials Network Cooperative Groups J. Clin. Oncol. 2022 40 1500 1505 35015566
Schöder, H. et al. Considerations on integrating prostate-specific membrane antigen positron emission tomography imaging into clinical prostate cancer trials by National Clinical Trials Network Cooperative Groups. J. Clin. Oncol. 40, 1500–1505 (2022).35015566
302. Roberts NJ Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses Sci. Transl. Med. 2014 6 249ra111 25122639
Roberts, N. J. et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci. Transl. Med. 6, 249ra111 (2014).25122639
303. McHale D P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity Ann. Oncol. 2020 31 S195
McHale, D. et al. P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity. Ann. Oncol. 31, S195 (2020).
304. Jackson CM Lim M Drake CG Immunotherapy for brain cancer: recent progress and future promiseimmunotherapy for brain cancer Clin. Cancer Res. 2014 20 3651 3659 24771646
Jackson, C. M., Lim, M. & Drake, C. G. Immunotherapy for brain cancer: recent progress and future promiseimmunotherapy for brain cancer. Clin. Cancer Res. 20, 3651–3659 (2014).24771646
305. Le DT Dubenksy TW Jr. Brockstedt DG Clinical development of Listeria monocytogenes-based immunotherapies Semin. Oncol. 2012 39 311 322 22595054
Le, D. T., Dubenksy, T. W. Jr. & Brockstedt, D. G. Clinical development of Listeria monocytogenes-based immunotherapies. Semin. Oncol. 39, 311–322 (2012).22595054
306. Hanna GJ Adkins DR Zolkind P Uppaluri R Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma Oral. Oncol. 2017 73 65 69 28939078
Hanna, G. J., Adkins, D. R., Zolkind, P. & Uppaluri, R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. Oral. Oncol. 73, 65–69 (2017).28939078
307. Uzunparmak B Sahin IH Pancreatic cancer microenvironment: a current dilemma Clin. Transl. Med. 2019 8 1 8 30604130
Uzunparmak, B. & Sahin, I. H. Pancreatic cancer microenvironment: a current dilemma. Clin. Transl. Med. 8, 1–8 (2019).30604130
308. Chervin CS Gajewski T Microbiome-based interventions: therapeutic strategies in cancer immunotherapy Immunooncol. Technol. 2020 8 12 20 35757563
Chervin, C. S. & Gajewski, T. Microbiome-based interventions: therapeutic strategies in cancer immunotherapy. Immunooncol. Technol. 8, 12–20 (2020).35757563
309. Morrow T Novartis’s Kymriah: harnessing immune system comes with worry about reining in costs Manag Care 2017 26 28 30 29068298
Morrow, T. Novartis’s Kymriah: harnessing immune system comes with worry about reining in costs. Manag Care 26, 28–30 (2017).29068298
310. Strimvelis K Yescarta L Gene therapy’s next installment Nat. Biotechnol. 2019 37 697 31267108
Strimvelis, K. & Yescarta, L. Gene therapy’s next installment. Nat. Biotechnol. 37, 697 (2019).31267108
311. Springer G Facharztmagazine R Tecartus®-chance auf dauerhaftes ansprechen beim mantelzelllymphom Info. Onkol. 2021 24 76 77
Springer, G. & Facharztmagazine, R. Tecartus®-chance auf dauerhaftes ansprechen beim mantelzelllymphom. Info. Onkol. 24, 76–77 (2021).
312. Jaklevic MC CAR-T therapy is approved for non-Hodgkin lymphoma J. Am. Med. Assoc. 2021 325 1032
Jaklevic, M. C. CAR-T therapy is approved for non-Hodgkin lymphoma. J. Am. Med. Assoc. 325, 1032 (2021).
313. CRS, C. R. S., NT, N. T. & Lymphohistiocytosis, H. US Food and Drug Administration approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the first anti-BCMA CAR T cell therapy for relapsed or refractory multiple myeloma. Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple survival. 5, 11–12 (2021).
314. Borogovac A Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center Bone Marrow Transplant. 2022 57 1025 1027 35411106
Borogovac, A. et al. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant. 57, 1025–1027 (2022).35411106
